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ABSTRACT
The goal of my dissertation was to compare and contrast the function of all
three major isoforms of Myosin Binding Protein-C (MyBP-C): slow-skeletal, fastskeletal, and cardiac (ssMyBP-C, fsMyBP-C, and cMyBP-C, respectively), with a focus
on the least characterized isoform, fsMyBP-C. Using a variety of ex vivo, in vitro, and
in silico methods, my research demonstrated that the N-terminal region of all MyBPC isoforms bind to actin and shift tropomyosin, thus activating the thin filament
during contraction. Furthermore, each isoform differentially activated the thin
filament over isoform-specific ranges of Ca2+: slow-skeletal activates at low Ca2+,
fast-skeletal activates at higher Ca2+, and cardiac activates over the full spectrum of
Ca2+. I propose that different expression of MyBP-C isoforms allow striated muscles
to fine tune its function. For example, the cardiac muscle sees the full range of Ca2+
on a beat-to-beat basis, and therefore cMyBP-C needs to operate over the full
spectrum of Ca2+ with much higher frequency. Conversely, various skeletal muscles
have vastly different roles: the demands of postural muscles are different than that
of phasic muscles; thus, varied expression of slow-skeletal and fast-skeletal MyBP-C
can ideally regulate the function of different muscles.
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CHAPTER ONE
INTRODUCTION
The clinical significance of understanding the role of Myosin Binding Protein-C
(MyBP-C) is clear: mutations in all three major isoforms of MyBP-C can cause
cardiac and skeletal muscle diseases. Notably, mutations in the cardiac isoform is
one of the most common causes of hypertrophic cardiomyopathy (HCM) (Bonne,
Carrier, Richard, Hainque, & Schwartz, 1998; Schlossarek, Mearini, & Carrier, 2011;
van Dijk et al., 2009; Watkins et al., 1995), with an estimated 60 million people
affected worldwide(Dhandapany et al., 2009). cMyBP-C mutations also cause dilated
cardiomyopathy (DCM)(Ehlermann et al., 2008; Hershberger et al., 2010). In
addition, mutations in the slow-skeletal and fast-skeletal isoforms have been
implicated in distal arthrogryposis, type 1 (DA1)(Bayram et al., 2016; Gurnett et al.,
2010), distal arthrogryposis, type 2 (DA2) (X. Li et al., 2015), and lethal congenital
contracture syndrome, type 4 (LCCS4)(Markus et al., 2012) (Figure 1).
The timeline of research into each of these isoforms is marked by the
discovery of links between the MyBP-C isoform and human disease. These links
demonstrate a clear and clinically relevant rationale to investigate its function, but
these links have been unearthed over a period of over two decades. Mutations in
cMyBP-C and myosin have long been implicated as the two major factors in the
development of HCM in patients
1
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(Geisterfer-Lowrance et al., 1990; Watkins et al., 1995), and has since spurred
increasing interest in the role of the cardiac isoform (Harris, Lyons, & Bezold, 2011;
Sadayappan & de Tombe, 2012). Within the past 6 years, studies have implicated the
ssMyBP-C in skeletal muscle disease, followed by a subsequent rise in interest in the
slow-skeletal isoform (Ackermann & Kontrogianni-Konstantopoulos, 2013; Gurnett
et al., 2010; Ha et al., 2013). Most recently, fsMyBP-C has been implicated in human
disease(Bayram et al., 2016). Just like the renewed interest in the slow-skeletal
isoform and the cardiac isoform before that, the discovery of a genetic link between
fsMyBP-C and muscle dysfunction in human patients is likely to stimulate attention
in the last of the three major MyBP-C isoforms.
Therefore, I focused my present dissertation on the biophysical mechanics of
fsMyBP-C. While the emphasis is on this overlooked isoform, the scope of my
dissertation research includes the slow-skeletal and cardiac isoforms. In doing so,
comparisons can be made to existing knowledge of MyBP-C, but more importantly,
this expanded scope allows a more comprehensive analysis of the MyBP-C as a
whole. Indeed, the research I have done has provided greater insight than the sum
of its parts on individual isoforms, and has led to both exciting and novel concepts
regarding the role of MyBP-C in muscle contraction.
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Figure 1. MyBP-C mutations cause muscle disease. The clinical significance of
studying Myosin Binding Protein-C (MyBP-C): mutations in MyBP-C cause
hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), distal
arthrogryposis type 1 (DA1), distal arthrogryposis type 2 (DA2), lethal congenital
contracture syndrome type 4 (LCCS4). Furthermore, MyBP-C is dysregulated in
diseases such as Duchenne muscular dystrophy (DMD) and limb-girdle muscular
dystrophy (LGMD). However, the function of MyBP-C has yet to be fully elucidated.

CHAPTER TWO
MYBP-C AND THE SARCOMERE
Introduction
Striated muscles consist of cardiac and skeletal muscles with vastly different
roles in the body, but its molecular mechanisms share some incredible similarities.
Striated muscle proteins (myofilaments) do not exist in isolation and have evolved
into a highly sophisticated ensemble with many contributing pieces. To affect
contraction at the whole muscle level, myofilament proteins work together in
concert with one another at the molecular level. At this level, the smallest functional
unit is known as a sarcomere. The sarcomere consists of thick and thin filaments
that slide across one another. This sliding action pulls the edges of the sarcomere
together and is the basis for contraction. Each thick and thin filament consists of its
own subset of myofilaments that operate via intricate intrafilament and
interfilament interactions during the contraction process. Thus, the goal of this
chapter is to introduce the myofilaments as they come into play during striated
muscle contraction.

4
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A Brief History
Major advancements have been made in our understanding of muscle
contraction at the molecular level since the initial discovery and isolation of the first
muscle protein, in 1864 by the German physiologist Wilhelm Kühne, which he called
myosin (Kühne, 1864). Subsequent work by Vladimir Engelhardt and Militza
Lyubimova in the late 1930s and 1940s demonstrated that myosin had enzymatic
activity capable of hydrolyzing ATP (Engelhardt, 1939). This ATPase activity drove
the interaction of myosin with the second major muscle protein, actin (Straub, 1943.
; Szent-Györgyi, 1943), discovered by Brunó Straub and Albert Szent-Györgyi. Then,
in the 1950s, the work led by Andrew Huxley and Rolf Niedergerke, and Hugh
Huxley and Jean Hanson demonstrated the sliding filament theory (A. F. Huxley &
Niedergerke, 1954a; H. Huxley & Hanson, 1954; H. E. Huxley, 1953), in which
contraction resulted from the interaction of myosin and actin filaments. Other
elements of these myofilaments were discovered around the same time or shortly
after: Kenneth Bailey and tropomyosin (Bailey, 1946, 1948), Setsuro Ebashi and
troponin (Ebashi & Endo, 1968; Ebashi & Kodama, 1965), and Gerald Offer and
Roger Starr (Offer, Moos, & Starr, 1973). The work by these and other pioneers have
laid the foundation for our understanding of striated muscle function.
Striated Muscles
Striated muscles consist both cardiac and skeletal muscle, which composes
30% and 38% of total body mass in women and men, respectively (Janssen,
Heymsfield, Wang, & Ross, 2000). Cardiac muscles in the heart are responsible for
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circulating blood throughout the body(Friedland, 2009; Harvey, 1628), and are
controlled by the autonomic nervous system(Robinson, Epstein, Beiser, &
Braunwald, 1966). The heart consists of cardiac muscle cells, or cardiomyocytes,
that are linked via intercalated discs in order to contract as a syncytium(Severs,
2000). These cardiomyocytes are usually bi-nucleated, and excitation-contraction
coupling (ECC)(Bers, 2002) is induced by a calcium-induced calcium release
(CICR)(Fabiato, 1983). Briefly, an electrical system travels via the T-tubules
resulting in an initial burst of Ca2+ from L-type voltage-dependent Ca2+-channels
known as dihydropyridine receptors (DHPR), which is detected by ryanodine
receptors (RyR) that release Ca2+ stores from sarcoplasmic reticulum (SR)(Fill &
Copello, 2002). Calcium is then able to initiate contraction, which will be explained
later in greater detail and can be summarized in Online Video 1
(https://vimeo.com/148663469). In contrast, skeletal muscle is responsible for
both support and voluntary movement of the body, controlled primarily by the
somatic nervous system. Skeletal muscle fibers are generally much larger than
cardiomyocytes, consist of different fiber types, and a single fiber can stretch from
tendon to tendon, from which force transmission is conducted(Schiaffino &
Reggiani, 2011). Skeletal muscle cells are multi-nucleated, having hundreds of nuclei
that dot the fiber from one end to another(Holtzer, Marshall, & Finck, 1957; Okazaki
& Holtzer, 1966). Contraction of individual skeletal muscle fibers depend on the
innervation of each fiber (Hughes, Kusner, & Kaminski, 2006). Activation of different
subsets of muscle fibers may not affect activation of adjacent muscle fibers. Unlike in
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cardiomyocytes, the electrical signal is transduced via neuromuscular junctions and
RyR are physically coupled to DHPR. In addition, skeletal muscle cells have known
regenerative capability, stemming from a reserve of satellite cells(Morgan &
Partridge, 2003; Yin, Price, & Rudnicki, 2013). While the role of cardiac and skeletal
muscles are distinct from one another, there are striking similarities in the
molecular mechanisms of contraction that regulate striated muscles. Specifically,
striated muscles have the same functional unit of contraction, known as the
sarcomere.
The Sarcomere is the Functional Unit of Muscle Contraction
The functional unit of muscle contraction at the molecular level is the
sarcomere, which comes from Greek sarx (flesh) and meros (part). (A. F. Huxley &
Niedergerke, 1954b; H. Huxley & Hanson, 1954). The sarcomere gives striated
muscles the striations that give them its name. These striations are visible by light
microscopy, and its highly organized and specific architecture is due to the
alignment of Z-disc proteins that delineate individual sarcomeres (Figure 2). Z-discs
are named from the German word “Zwischenscheibe,” meaning “between discs.” In
the middle of the sarcomere is the M-line, from the German word “Mittelscheibe,”
meaning “center disc.” Using electron microscopy, two distinct bands are clearly
visible: a light band (I-band) and a dark band (A-band), because these regions of the
sarcomere are isotropic and anisotropic to polarized light, respectively. Within the
darker A-band is a region called the H-zone, after the German word “heller.” These
various regions are populated by thin and thick filaments that overlap one another
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to create the varying densities that make up each region. The thin and thick filament
proteins run parallel to one another and perpendicular to the Z-discs. The thin and
thick filaments overlap and slide one another to affect contraction at the molecular
level. This event is triggered by Ca2+ activation of the thin filament, a process in
which Ca2+-binding to the troponin (Tn) complex shifts tropomyosin’s (Tm) position
along the thin filament from a “blocked” to a “closed” position, which exposes
myosin-binding sites on actin (Kobayashi & Solaro, 2005). Once the myosin head
binds to actin, myosin and actin undergo a transition from weak to strong binding,
further shifting tropomyosin to the “open” position, thus fully activating the thin
filament. During this process, myosin hydrolyzes ATP (ATPase), converting chemical
energy to mechanical energy, thus providing the power to slide thin filaments over
the thick filaments (H. Huxley & Hanson, 1954; Spudich, 2001). Due to its central
location between thick and thin filaments, MyBP-C is thought to modulate
contraction through its effects on both thin filament activation and cross-bridge
power generation.

9

Figure 2. MyBP-C and the sarcomere. Top-down schematic of the location of
Myosin Binding Protein-C (MyBP-C) in muscle at the molecular level. Muscles
consists of bundles of muscle fibers, known as fascicles (top). Muscle fibers, or
myofibrils, are composed of sarcomeres, individual functional units of contraction
(middle). MyBP-C is localized specifically within the C-zone of the sarcomere in 7-9
transverse stripes flanking the M-line. Each sarcomere is delineated by the Z-disc,
with thick and thin filaments that overlap in the center. The thick filament primarily
consists of myosin, and thin filaments are composed of actin, troponin, and
tropomyosin (bottom). MyBP-C interacts with both the thick and thin filaments, with
its C-terminus anchoring on the myosin LMM region and titin, and N-terminus
interacting with myosin S2 region and actin.
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The Thin and Thick Filaments of the Sarcomere
Thin filaments consist primarily of actin that form a helical rope attached at
the Z-discs. The actin filament is capped at the Z-discs by CapZ proteins and
tropomodulin towards the M-line. Spanning the length of the thin filament is the
giant protein, nebulin. Along the length of actin are tropomyosin, which also forms a
helical structure, and periodically dotted by troponin complex proteins. Thick
filaments consist primarily of myosin, which consists of multiple subfragments.
Myosin is the motor that physically interacts with actin to slide the filaments across
one another. Myosin itself consists of several distinct regions, including the head
domain, neck domain, and tail domain. Spanning the length of the thick filament is
the giant protein, titin. Within the A-band is an even darker region, known as the Czone. The C-zone consists of Myosin Binding Protein-C (MyBP-C). This chapter will
highlight aspects of these myofilament proteins in the order they come into play
during contraction.
Troponins: TnC, TnI, TnT
In both cardiac and skeletal muscles, molecular contraction at the sarcomeric
level is initiated by Ca2+. The influx of Ca2+, and the signal it carries, is detected and
transduced by the troponin complex, which consists of three subunits Troponin C,
Troponin I, and Troponin T (TnC, TnI, TnT, respectively) (Figure 2). As previously
mentioned, initial discovery is largely attributed to the work by Setsuro Ebashi
(Ebashi & Endo, 1968), and much has since been learned regarding their function..
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TnC binds Calcium
After Ca2+ is released into the sarcomere, the first troponin to come into play
is TnC, the 18 kDa troponin subunit that binds Ca2+, specifically within the Nterminal regulatory domains. TnC structure consists of two globular domains at the
N- and C-terminal ends (Herzberg & James, 1988; Satyshur et al., 1988)connected
via α-helical bridge (Vassylyev, Takeda, Wakatsuki, Maeda, & Maeda, 1998). The Nterminal globular domain is thought to be the primary regulation region, capable of
binding Ca2+ via one of four EF hand motifs (van Eerd & Takahashi, 1975), while the
C-terminal domain is thought to serve a structural role. EF hand motifs are
numbered Sites I – IV, with N-terminal sites (I and II) having relatively low affinity
to Ca2+ compared to C-terminal sites (III and IV). However, sites III and IV are
occupied by Mg2+ under physiological conditions (Zot & Potter, 1987). Interestingly,
the C-terminus also has the EF hand motif, and evidence suggests some contribution
to regulatory function (Biesiadecki, Kobayashi, Walker, Solaro, & de Tombe, 2007).
The N-terminal domain of TnC interacts with the C-terminal region of TnI dubbed
the “regulatory head” (Kleerekoper, Howarth, Guo, Solaro, & Rosevear, 1995;
Takeda, Yamashita, Maeda, & Maeda, 2003), and the binding of Ca2+ to the Nterminal globular domain alters its interaction with TnI. The conformational change
in the regulatory head transduces the Ca2+ signal.
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TnI is the inhibitory subunit
TnI undergoes a conformational change, induced by Ca2+-binding to TnC, and
this structural change is a vital step in thin filament activation. TnI is a 21 kDa
troponin subunit known to be an important inhibitor of sarcomeric activation due to
its interactions with the other troponin subunits, as well as tropomyosin and actin
(Ohtsuki, Maruyama, & Ebashi, 1986; Zot & Potter, 1987). TnI inhibits actomyosin
Mg-ATPase, and this inhibition is enhanced by tropomyosin (Greaser & Gergely,
1971; Potter & Gergely, 1974). TnI has been demonstrated to be a potent regulator
of Ca2+-sensitivity that is also highly regulated by phosphorylation (Layland, Solaro,
& Shah, 2005; Solaro & Van Eyk, 1996; Westfall & Metzger, 2001; Westfall, Turner,
Albayya, & Metzger, 2001), with the central region of TnI primarily for both actin
binding and inhibitory capacity(Syska, Wilkinson, Grand, & Perry, 1976; Talbot &
Hodges, 1981), with some contributions to inhibitory activity from the N-terminal
region(Sheng, Pan, Miller, & Potter, 1992), as well as the C-terminal region (Farah et
al., 1994). In its inactivated state, N-terminal region of TnI loosely binds TnC and
TnT, while its C-terminal region tightly binds actin. Its binding affinities change
upon activation by Ca2+: TnC binding to Ca2+ causes TnI to tightly bind TnC and TnT,
while loosening its binding to actin(Potter & Gergely, 1974; Syska et al., 1976). This
change is thought to transduce the signal down to the last troponin subunit, TnT.
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Troponin T binds tropomyosin
TnT is the largest of the troponin subunits at 36 kDa, and TnT anchors the
other troponin subunits to the actin filament, as well as binding to tropomyosin
(Tm) (Hitchcock, 1975a, 1975b; Hitchcock & Lutter, 1975). The structure of TnT
consists of two helical structures (T1 and T2), as well as an unstructured flexible
region known as the hypervariable domain (Takeda et al., 2003). The C-terminal T2
structure interacts with TnI, TnC, and actin(Heeley, Golosinska, & Smillie, 1987;
Schaertl, Lehrer, & Geeves, 1995), as well as the central region of Tm(Morris &
Lehrer, 1984; Pearlstone & Smillie, 1982). The central T1 region interacts with Cterminus of Tm; however, the function of the N-terminal hypervariable domains (H1
and H2) remains unclear, though these regions may allow TnT to adapt to specific
isoforms, muscles, or species (Biesiadecki, Chong, Nosek, & Jin, 2007; Jin, Chen, Ogut,
& Huang, 2000). The primary role for TnT is thought to be structural, but recent
studies suggest TnT has several phosphorylation sites that regulate Ca2+-sensitivity
and force generation (Jideama, Crawford, Hussain, & Raynor, 2006; Noland & Kuo,
1992; Sumandea, Pyle, Kobayashi, de Tombe, & Solaro, 2003). The interaction
between Tm and TnT is likely the primary mechanism behind its regulation of thin
filament activation. (Pato, Mak, & Smillie, 1981; White, Cohen, & Phillips, 1987)TnT
loosens its interaction with Tm, which allows Tm to move its position relative to
actin in such a way that exposes the myosin-binding site on actin (Potter, Sheng,
Pan, & Zhao, 1995).
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Tropomyosin
Tropomyosin (Tm) is a 37 kDa, 42nm-long protein that, much like actin,
consists of double α-helices that form a coiled-coil that intertwines with the actin
filament (Woods, 1966, 1967). There are multiple isoforms of Tm, such as α-Tm, ßTm, and slow α-Tm, encoded by TPM1, TPM2, and TPM3, respectively (Perry, 2001).
These isoforms are structurally similar, but variations in structural homology
suggest variations in their capacity to regulate contraction at the molecular
level(Muthuchamy et al., 1995). Tm polymers can form both homodimers and
heterodimers, though in striated muscles Tm is arranged in heterodimers (Jancso &
Graceffa, 1991; Lehrer, Qian, & Hvidt, 1989) that overlap by 8-9 amino acids from
the N-terminus of one Tm polymer with the C-terminus of another (McLachlan &
Stewart, 1975). Similar to one of its binding partners, TnT, Tm is thought to stabilize
thin filaments: its interactions in conjunction with tropomodulin reduce
depolymerization of the thin filament. Functionally, Tm works in tandem with Tn to
regulate thin filament activation, and thus, myosin-actin interaction. Tm isoforms
dimerizes and polymerizes end-to-end, fitting into the major groove within the actin
double α-helix(Perry, 2001). In this groove, Tm physically blocks the myosinbinding site on actin, thus preventing contraction by interfering with myosin and
actin interactions (Fraser & Marston, 1995). The conformational shift induced by
Ca2+-bound troponin causes Tm to shift from the blocked to closed position, which
exposes the myosin-binding sites on actin(McKillop & Geeves, 1993). The binding of
myosin to actin further shifts the position of Tm on actin from the closed to open
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position(Rosol et al., 2000).
Actin
The thin filament is primarily composed of actin filaments which, like
tropomyosin, consists of double α-helices that form a coiled-coil within the
sarcomere (Holmes, Popp, Gebhard, & Kabsch, 1990; Lorenz, Poole, Popp,
Rosenbaum, & Holmes, 1995). Globular actin (G-actin) polymerizes into filamentous
actin (F-actin) in a spontaneous manner, which then forms the major element of the
thin filament. G-actin consists of 4 subdomains (SD1-SD4) (Kabsch, Mannherz, Suck,
Pai, & Holmes, 1990; McLaughlin, Gooch, Mannherz, & Weeds, 1993; Schutt,
Lindberg, Myslik, & Strauss, 1989), which forms a binding pocket for a nucleotide
(ADP and ATP) (Egelman & Orlova, 1995; Kinosian, Selden, Estes, & Gershman,
1993a, 1993b) and for a divalent ion (Mg2+ or Ca2+) (Orlova & Egelman, 1995;
Orlova, Prochniewicz, & Egelman, 1995). There are 7 actin monomers per halfhelical turn of the actin filament, which interact with its opposing strand via
subdomains (SD) 3 and 4, while subdomains 1 and 2 can interact with other
myofilament proteins, such as myosin and MyBP-C (Figure 3). Subdomains on the
actin monomer also interacts with other contractile proteins(von der Ecken et al.,
2015). Vertebrate actin is composed of three main isoforms that are highly
homologous (α, β, and γ), and skeletal, cardiac, and smooth variations of the α
isoform (Vandekerckhove & Weber, 1979). The skeletal and cardiac isoforms are
differentially expressed, and expression varies on muscle type and species.
However, actin isoforms are highly conserved, with only minimal variation at the N-
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terminal region(Vandekerckhove & Weber, 1979), though differences of just 15
amino acids can result in structural and functional variations(Brault, Reedy, et al.,
1999; Brault, Sauder, Reedy, Aebi, & Schoenenberger, 1999). The importance of
actin function is clear: actin is the primary component of the thin filament that
serves to anchor troponins and tropomyosin. In addition, actin functions to
transduce force generation via interactions with thick filament proteins, most
notably, myosin. Specifically, actin subdomain 1 (SD1) binds to the myosin head
(also known as the myosin subfragment 1 or myosin S1) primarily via two known
ionic interactions: 1) the negative charge of SD1 interacts with the positivelycharged lysine myosin 50k/20k loop 2) an adjacent SD1 interacts with myosin
amino acid residues 567-578(Milligan, 1996; Milligan, Whittaker, & Safer, 1990;
Rayment, Holden, et al., 1993). A third interaction occurs between myosin S1 (amino
acids 404-415) with the proline residues in between actin SD1 and SD3.
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Figure 3. Actin has four subdomains. Actin monomer is the base unit of the actin
filament (F-actin), which is a helical coiled-coil. There are 4 primary subdomains
(SD) on the actin monomer that interact with other thick and thin filament
proteins. SD1 is the primary binding site for myosin S1 region (represented by the
green circle), which also is known to interact with the pocket between SD1 and
SD3. SD3 and SD4 are primarily responsible for actin-actin interactions.
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Myosin
Myosin is a superfamily of proteins with many classes and functional
roles(Foth, Goedecke, & Soldati, 2006; Krendel & Mooseker, 2005; Woolner &
Bement, 2009). This section will focus on the class 2 myosin in striated muscles that
form the cross-bridge, which is responsible for muscle contraction. Myosin M2 was
originally discovered in 1864 by Wilhelm Kühne (Kühne, 1864). The thick filament
primarily consists of myosin, a large 220 kDa protein responsible for binding to
actin and pulling the thin and thick filaments across one another to affect
contraction. Myosin itself consists of several distinct regions: the head, neck, and tail
regions. The N-terminal region has two heads, each known as the S1
subfragment(Dominguez, Freyzon, Trybus, & Cohen, 1998; Rayment, Holden, et al.,
1993; Rayment, Rypniewski, et al., 1993). The S1 subfragment projects outward
from the thick filament at 14.3 nm intervals and physically interacts with actin to
form cross-bridges. The catalytic head is the motor of sarcomeric muscle
contraction (Toyoshima et al., 1987) and is primarily responsible for the sliding of
the thick and thin filaments across one another, and has nucleotide binding pocket
capable of converting chemical energy (ATP) into mechanical energy (Holmes,
Angert, Kull, Jahn, & Schroder, 2003). In the rigor state, myosin is attached to actin,
with ADP and inorganic phosphate attached. The release of ADP and inorganic
phosphate results in the myosin head to shift in such a way that it pulls on the actin
thin filament, in what is known as the powerstroke. As ATP binds to the myosin
head, myosin detaches from actin. Myosin MgATPase activity hydrolyzes the ATP
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into ADP and inorganic phosphate, repositioning the myosin head in its original
position, and the cycle begins anew (Holmes et al., 2003)(Figure 2). Just below the
S1 subfragment is the myosin neck, S2 subfragment, and the S2 region links the
myosin head to the rest of the thick filament. In addition, the S2 region interacts
with two myosin light chains (MLC) thought to fine-tune myosin function: the
essential light chain (ELC) and regulatory light chain (RLC). Further towards the Cterminus is the light meromyosin (LMM), and the LMM forms the coiled coil that
anchor myosin to the thick filament, where it interacts with titin and Myosin
Binding Protein-C.
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Figure 4. There are three isoforms of MyBP-C: slow-skeletal, fast-skeletal, and
cardiac, encoded by its own gene: MYBPC1, MYBPC2, and MYBPC3, respectively. All
isoforms share a conserved structure of immunoglobulin (blue circle) and
fibronectin (orange hexagon) –like domains, numbered C1 through C10. All
isoforms also have a M-motif (red circle), as well as a proline-alanine (P/A) rich
region (purple rectangle). However, there are significant differences between
isoforms, particularly in the N-terminal region of MyBP-C. First, cardiac MyBP-C
consists of an additional N-terminal domain, known as the C0 domain. Second, the
location of phosphorylation sites are different: cardiac MyBP-C has 4 sites in the
M-motif and 1 in the P/A region, while slow-skeletal has 3 sites in the P/A region
and 1 in the M-motif. Fast-skeletal MyBP-C currently has no identified
phosphorylation sites. The function of all three N-terminal regions have never been
fully elucidated
Myosin Binding Protein-C
Interaction between myosin and actin is regulated by Myosin Binding
Protein-C (MyBP-C), which was first discovered as a myosin impurity in the 1970s
(Craig & Offer, 1976; Offer et al., 1973). The three distinct MyBP-C isoforms: slowskeletal, fast-skeletal, and cardiac, are each encoded by a distinct gene (MYBPC1,
MYBPC2, MYBPC3, respectively)(Carrier et al., 1993; Weber, Vaughan, Reinach, &
Fischman, 1993) (Figure 4). MyBP-C isoforms are localized within the Czones(Offer et al., 1973), a region within the sarcomere flanking the M-line(Gilbert,
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Cohen, Pardo, Basu, & Fischman, 1999), arranged in 7-9 transverse stripes at 43 nm
intervals(Bennett, Craig, Starr, & Offer, 1986; Dennis, Shimizu, Reinach, & Fischman,
1984; Flashman, Redwood, Moolman-Smook, & Watkins, 2004; Rome, Offer, & Pepe,
1973) (Figure 2). As the names suggest, slow-skeletal and fast-skeletal isoforms
(ssMyBP-C and fsMyBP-C, respectively) are expressed in skeletal muscles, whereas
the cardiac isoform (cMyBP-C) predominates in the heart(Gautel, Furst, Cocco, &
Schiaffino, 1998), though complexities of expression are further discussed in
Chapter Three. The 43 nm interval of MyBP-C and 14.3 nm interval of myosin heads
correlates to 1:3 ratio between MyBP-C and myosin within the C-zone(Craig & Offer,
1976; Luther & Craig, 2011). MyBP-C structure consists of seven immunoglobulin
and three fibronectin III domains, numbered C1 through C10, from the N-terminus
to the C-terminus(Luther et al., 2011). In addition, there is a proline/alanine-rich
(PA) region that precedes the C1 domain, as well as a M motif between the C1 and
C2 domains(Barefield & Sadayappan, 2010; Gautel, Zuffardi, Freiburg, & Labeit,
1995; Kuster et al., 2012). Despite these similarities, MyBP-C isoforms are
structurally distinct and there are many key differences within the N-terminal
region. Cardiac MyBP-C has an additional immunoglobulin-like domain, the C0
domain(Ratti, Rostkova, Gautel, & Pfuhl, 2011), as well as five known
phosphorylation sites: four within the M motif(Copeland et al., 2010; Mohamed,
Dignam, & Schlender, 1998) and one in the PA region(Kuster et al., 2013).
Conversely, slow-skeletal MyBP-C has one known phosphorylation site in the M
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motif and three phosphorylation sites in the PA region(Ackermann & KontrogianniKonstantopoulos, 2011a). Currently, no phosphorylation sites have been identified
in fast-skeletal MyBP-C, but evidence suggest the presence of phosphorylation sites
due to changes in the phosphorylation state of both ssMyBP-C and fsMyBP-C during
disease(Ackermann, Kerr, King, C, & Kontrogianni-Konstantopoulos, 2015;
Ackermann et al., 2013; Ackermann, Ward, Gurnett, & KontrogianniKonstantopoulos, 2015).
MyBP-C primarily operates via protein-protein interactions due to the lack of
evidence of enzymatic activity, nor interactions with nucleic acids and sugars(Pfuhl
& Gautel, 2012), though a low-affinity zinc binding site has been reported in the C1
domain of MyBP-C(Ababou et al., 2008), the vast majority of studies conducted in
MyBP-C focuses on its interactions with other myofilament proteins.
The C-terminal region of MyBP-C has been demonstrated to interact with
both the light meromyosin (LMM) region of myosin(Miyamoto, Fischman, &
Reinach, 1999; Moos, Offer, Starr, & Bennett, 1975; Okagaki et al., 1993) and
titin(Freiburg & Gautel, 1996; Furst, Vinkemeier, & Weber, 1992) of the thick
filament, with the C8 through C10 domains being vital for localization to the A-band
of the sarcomere(Gilbert et al., 1999). MyBP-C interaction with titin in particular is
thought to be important for determining localization and periodicity of MyBP-C
within the sarcomere(Furst et al., 1992; Koretz, Irving, & Wang, 1993): titin PEVK
super repeats (a series of immunoglobulin and fibronectin III domains) act as a
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scaffold for MyBP-C within the sarcomere(Labeit, Gautel, Lakey, & Trinick, 1992;
Trinick, 1992, 1994). The C-terminal domains may also participate in the
organization and stability of thick filaments during development (Nyland et al.,
2009). However, cMyBP-C knock-out mouse models of cardiomyopathies have
demonstrated sarcomere structures are still conserved (Harris et al., 2002;
McConnell et al., 1999). Normal sarcomere structure is observed in human patients
with MyBP-C mutations that result in hypertrophic cardiomyopathy and distal
arthrogryposis type 1(Vydyanath, Gurnett, Marston, & Luther, 2012), suggesting
that MyBP-C role in sarcomeric assembly is not absolutely necessary. Though the
MyBP-C C-terminal domains anchors MyBP-C to the thick filament, the MyBP-C Nterminal binding partners are more varied and functional implications more
complex.
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Function of MyBP-C
MyBP-C has been known as the braking mechanism in cardiac muscle
contraction (Previs, Beck Previs, Gulick, Robbins, & Warshaw, 2012; Razumova et
al., 2006), due to its ability to reduce thin filament sliding velocities. Furthermore,
the N-terminal region of MyBP-C have been demonstrated to bind to actin and shift
tropomyosin from the blocked to closed position, in a similar manner to Ca2+-bound
Tn complex(Mun et al., 2014). Studies using recombinant proteins representing the
cMyBP-C N-terminus have demonstrated that cMyBP-C has a significant effect in
promoting Ca2+-sensitivity and rate of tension redevelopment(Razumova, Bezold,
Tu, Regnier, & Harris, 2008; Witayavanitkul et al., 2014). The functional mechanism
of MyBP-C is likely due to interactions with actin(Shaffer & Harris, 2009; Squire,
Luther, & Knupp, 2003; Whitten, Jeffries, Harris, & Trewhella, 2008), myosin
subfragment-2 (S2)(Gruen & Gautel, 1999; Gruen, Prinz, & Gautel, 1999; Moos et al.,
1975; Offer et al., 1973; Starr & Offer, 1978), and regulatory light chain of
myosin(Ratti et al., 2011). The primary interaction MyBP-C with the thin filament is
via actin: the C1 domain and M-motif are required for interaction with
actin(Bhuiyan, Gulick, Osinska, Gupta, & Robbins, 2012; Squire et al., 2003; Whitten
et al., 2008), although the cardiac-specific C0 domain of cMyBP-C has been
demonstrated to be sufficient to interact with actin and elicit some functional
effects(Herron et al., 2006). This indicates MyBP-C interaction with actin likely
involves several N-terminal domains. In contrast, MyBP-C interaction with myosin
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subfragment-2 appears to be limited to the M-motif, specifically the N-terminal 126
residues of S2(Gruen & Gautel, 1999), and may be mutually exclusive to MyBP-C
interaction with actin(Bhuiyan et al., 2012; Gruen & Gautel, 1999). However, there is
some discrepancy within the literature on what this entails at the functional level.
Kunst et al. 2000 demonstrated that the C0 domain alone does not interact with
myosin(Kunst et al., 2000), while others demonstrated C0 does interact with the
regulatory light chain (RLC) of myosin (Ratti et al., 2011). Interestingly, Herron et al.
2006 demonstrated C0 domain alone is able to elicit some functional effects (Herron
et al., 2006), suggesting the C0 domain regulates function via interactions with actin.
Studies demonstrating MyBP-C N-terminus binding to actin and myosin
suggest a unique orientation between the thin and thick filaments, as well as
promiscuity with multiple binding partners that is regulated in a phosphorylationdependent manner(Barefield & Sadayappan, 2010; Sadayappan & de Tombe, 2012)
(Figure 4). Kulikovskaya et al. (2003) demonstrated that phosphorylation of
cMyBP-C ablates its interaction with myosin subfragment-S2, thus resulting in
greater force production by allowing myosin to bind to actin(Kulikovskaya,
McClellan, Flavigny, Carrier, & Winegrad, 2003). Specifically, phosphorylation of
MyBP-C regulatory sites (S276, S285, S304 in humans) results in the N-terminal
region to favor binding with actin versus myosin. By this mechanism, cMyBP-C is
thought to provide regulation at multiple levels during contraction. First, MyBP-C
interaction with myosin is hypothesized to act as a mechanical load on myosin, and
thus reduce its ability to form cross-bridges. Phosphorylation of MyBP-C releases
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this load on myosin, thereby promoting cross-bridge cycling kinetics. Recent studies
demonstrated phosphorylation of the M-motif of cMyBP-C confers a specific
structural stiffness to the region and results in a conformation change in the Nterminal region(Colson, Thompson, Espinoza-Fonseca, & Thomas, 2016; Previs et
al., 2016). In these studies, phosphorylation causes the N-terminal region of cMyBPC to fold on itself, perhaps shielding interacting residues within the M-motif that are
responsible for myosin binding. This would subsequently free the MyBP-C Nterminus for interaction with actin, to facilitate contraction. However, this
conformational effect is ablated at high Ca2+ (Previs et al., 2016), suggesting that
MyBP-C N-terminus would once again favor myosin binding. This model allows for
binding of MyBP-C to both myosin and actin, at different stages of contraction (low
and high Ca2+), but whether the binding interactions are mutually exclusive has yet
to be resolved.

CHAPTER THREE
EXPRESSION PROFILE OF THE THREE MYBP-C
2.1 Structures of MyBP-C isoforms are both similar and distinct
MyBP-C is a family of thick filament contractile proteins with three
predominant isoforms: slow-skeletal, fast-skeletal, and cardiac (ssMyBP-C, fsMyBPC, and cMyBP-C, respectively), which are expressed by individual genes (MYBPC1,
MYBPC2, MYBPC3, respectively). It is worth mentioning the existence of an
additional isoform, MyBP-H (encoded by MYBPH gene), whose structure resembles
that of the C-terminal half of MyBP-C(Gilbert et al., 1999; Vaughan, Weber, Einheber,
& Fischman, 1993). As mentioned in the Chapter Two, MyBP-C isoforms share
several conserved structural elements, including seven immunoglobulin and three
fibronectin III domains, numbered C1 through C10, from the N-terminus (Luther &
Vydyanath, 2011), a proline/alanine-rich (PA) sequence preceding the C1 domain,
and a conserved M domain between the C1 and C2 domains (Figure 4). Where the
notable differences exist between MyBP-C isoforms is within their N-terminal
regions. For example, cMyBP-C has an additional immunoglobulin-like “C0” domain
of approximately 100 amino acids, which binds myosin light regulatory chain and
actin in vitro (Gautel et al., 1995; Ratti et al., 2011). In addition, cMyBP-C has 4
phosphorylation sites in the M domain (Barefield & Sadayappan, 2010) and one in
the PA region (Kuster et al., 2013), whereas ssMyBP-C has one phosphorylation site
27
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in the M domain and three in the PA region (Ackermann & KontrogianniKonstantopoulos, 2011a) and no phosphorylation sites have yet to be identified in
fsMyBP-C. Sequence identity between isoforms is also reduced in this N-terminal
region (Table 1). Further differences are notable in the C5 domain of cardiac, in
which cMyBP-C has an additional flexible insert of unknown function (Cecconi,
Guardiani, & Livi, 2008; Guardiani, Cecconi, & Livi, 2008a, 2008b; Idowu, Gautel,
Perkins, & Pfuhl, 2003), though more recent studies have suggested that this confers
the ability to bend at particular hinge points centering around the C5 domain(Previs
et al., 2016)
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MyBP-C

ssC1C2

fsC1C2

C0C2

N-termini

(a.a. 1-341)

(a.a. 1-337)

(a.a. 1-448)

NCBI
Accession
Number

NP_780627.2

NP_666301.2

AAI54409.1

ssC1C2

Identity

Positives

Gaps

Identity

Positives

Gaps

53%

70%

5%

52%

67%

6%

48%

59%

8%

fsC1C2
MyBP-C Full
Length

ssMyBP-C
fsMyBP-C

ssMyBP-C

fsMyBP-C

cMyBP-C

Identity

Positives

Gaps

Identity

Positives

Gaps

51%

70%

2%

49%

67%

5%

53%

68%

4%

Table 1. N-terminal homology between N-terminal MyBP-C proteins (ssC1C2, fsC1C2,
C0C2) and full-length MyBP-C.
2.2 Skeletal isoforms of MyBP-C are present in the heart
As the names suggest, cardiac MyBP-C predominates in the heart, while slowand fast-skeletal MyBP-C predominates in skeletal muscles. Contrary to common
belief, the expression profile of MyBP-C isoforms is much more complicated in
development versus adult stages and healthy versus disease states. For example,
avian species temporarily expresses cMyBP-C in skeletal muscles during embryonic
development(Bahler, Moser, Eppenberger, & Wallimann, 1985; Kawashima, Kitani,
Tanaka, & Obinata, 1986; Obinata et al., 1984), though cMyBP-C expression is not
observed during mammalian embryonic development at the transcript nor protein
level (Gautel et al., 1998; Kurasawa et al., 1999). However, an embryonic isoform is

30
expressed in mammalian cardiac and skeletal muscles(Gautel et al., 1998), after
which the cardiac and skeletal MyBP-C isoforms begin to predominate their
respective muscles. The authors argued that during adulthood, cardiac and skeletal
MyBP-C were specifically expressed in cardiac and skeletal muscles, respectively,
though later studies demonstrated that was not necessarily the case. Adding further
complication to our understanding of MyBP-C expression patterns, ssMyBP-C was
detected in the heart (Dhoot & Perry, 2005), albeit in small quantities in the right
atrium and interatrial septum. Perhaps most surprisingly, the cardiac samples used
in this study were from healthy tissues and not diseased hearts.
This led us to suspect the expression of MyBP-C isoforms may be altered due
to different conditions during disease states. To test this, we used a murine mouse
model of heart failure, the cMyBP-C-/- knock-out mouse known as the (t/t) mouse
(McConnell et al., 1999). The t/t mouse expresses a truncated cMyBP-C, which is not
incorporated properly within the sarcomere and degraded, creating a functional
knock-out. Using hearts from these t/t mouse, we demonstrated the presence of
fsMyBP-C in the heart during heart failure (B. Lin et al., 2013), indicating expression
patterns of MyBP-C can shift due to physiological or pathophysiological conditions
in the heart. To further investigate whether expression of fsMyBP-C was specific to
this transgenic mouse model in which cMyBP-C was completely absent, I conducted
preliminary investigations in other transgenic mouse models of HF, as well as a
pressure-overload mouse model of HF. In addition to the t/t mouse heart samples,
our lab studies other mouse models of heart failure, known as the 110 and C10 mice,
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which have truncations in the N-terminal and C-terminal regions of cMyBP-C,
respectively. In addition, I analyzed the hearts from mice that have undergone TAC
(transaortic constriction), in which the aortic opening is sutured to induce pressureoverload hypertrophy of the ventricle. In the TAC mouse model, we have previously
demonstrated that fsMyBP-C expression is increased at the transcript level (Figure
5). While this suggests fsMyBP-C may be upregulated, it is not a foregone conclusion
that fsMyBP-C protein levels increase. The hearts from mouse models were
compared to non-transgenic controls, while hearts from TAC mice were compared
with sham surgery controls. Our preliminary results revealed that insult to the
heart, in general, can result in the upregulation of fsMyBP-C expression in the heart
at the protein level (Figure 6). Western blot analysis determined the presence of
fsMyBP-C in all mouse models of HF that we tested. In addition to previously
published evidence demonstrating the presence of small amounts of fsMyBP-C in
the t/t mice, 110 mice and C10 mice also expressed comparable quantities of
fsMyBP-C (Figure 6). Furthermore, fsMyBP-C was also detected in TAC mouse
hearts, suggesting that the upregulation of fsMyBP-C was related to the diseased
condition of the heart rather than a specific compensatory upregulation due to
transgenic modification of cMyBP-C. I theorize that upregulation of fsMyBP-C in the
heart in disease may be reflective of a reversion to fetal programming, commonly
observed in the diseased heart in which genetic programming reverts to conditions
similar to embryonic development gene programming (Olson, 2004; Razeghi et al.,
2001). Regulation of this phenomena is highly regulated, (Dirkx, da Costa Martins, &
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De Windt, 2013; Dirkx, Gladka, et al., 2013), though much has yet to be
elucidated. Some studies suggest the reversion to fetal programming is initially
compensatory (Olson, 2004; Razeghi et al., 2001), but continued activation of fetal
gene programming is detrimental to the long-term health of the heart (Olson, 2004).
It should be noted that mouse hearts from even sham-surgery also exhibited
upregulation of fsMyBP-C, suggesting even slight insults to the heart may result in
fsMyBP-C upregulation and/or strain differences in the mouse models used (FVB/N
versus C57BL background).
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Figure 5. Increased fsMyBP-C transcript levels in pressure-overload mouse model,
as induced by TAC surgery. RNA Seq (top row) and qPCR (bottom row)
demonstrate increased relative expression of MYBPC2, the gene encoding fastskeletal MyBP-C, but not MYBPC3, the gene encoding cardiac MyBP-C. MYH7, the
gene encoding ß-myosin heavy chain was also elevated. Housekeeping genes
GAPDH and CASQ2 were also analyzed as controls and were unchanged. TAC mice
data courtesy of Dr. Dave Barefield.
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Figure 6. Skeletal MyBP-C may be present in the heart. Hearts from multiple
mouse models of heart failure were examined for possible expression of ssMyBPC and fsMyBP-C. The t/t mouse model is a functional cMyBP-C knock-out, C10
mouse lacks the C-terminal region of cMyBP-C, and the 110 mouse lacks the Nterminal region of cMyBP-C. TAC mice are pressure-overload models of HF. Heart
lysates courtesy of Thomas Lynch and Dave Barefield.
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2.3 Expression profile of ssMyBP-C and fsMyBP-C in skeletal muscles
The expression profile of ssMyBP-C and fsMyBP-C is also complicated in
skeletal muscles. The literature provides little insight into ssMyBP-C(Ackermann &
Kontrogianni-Konstantopoulos, 2013; Gurnett et al., 2010; Ha et al., 2013) and even
less so concerning fsMyBP-C(Colson, Rybakova, Prochniewicz, Moss, & Thomas,
2012; M. Li, Andersson-Lendahl, Sejersen, & Arner, 2016). Based on the name “slowskeletal” and “fast-skeletal,” it was often assumed was that ssMyBP-C was expressed
in “slow-type” muscles and fsMyBP-C was expressed in “fast-type” muscles. Like the
assumptions made regarding MyBP-C expression profile in the heart, the reality is
much more complicated. Employing the same methods to determine expression
profile in the heart, I determined the expression profile of ssMyBP-C and fsMyBP-C
in skeletal muscles. Despite its expression in skeletal muscles of avian species
during development(Bahler et al., 1985; Gautel et al., 1995; Obinata et al., 1984), I
did not determine cMyBP-C expression in skeletal muscles, because it has been
convincingly demonstrated not to be expressed at all in skeletal muscles of
mammalian species(Gautel et al., 1998; B. Lin et al., 2013). This endeavor was
complicated by several factors. First, skeletal muscles encompass a variety of
different muscles that all have very distinct roles in providing postural and
locomotor support for the body. Second, within a specific type of skeletal muscle,
slow- and fast-type muscle fibers can co-exist adjacent to one another, or even slow
and fast isoforms of the same protein within the same fiber. Third, there are
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different methods of classifications of skeletal muscle fiber types, such as myosin
ATPase activity, myosin fiber types, and biochemical analysis.
Therefore, to determine the expression profile of ssMyBP-C and fsMyBP-C,
several different skeletal muscles were selected for analysis, particularly those used
previously in the skeletal literature to represent slow, fast, and mixed fiber types.
These muscles included the SOL (soleus), a slow-oxidative muscle and commonly
used to represent slow-type muscles(Lutz, Ermini, & Jenny, 1978; Rubinstein &
Kelly, 1981); EDL (extensor digitorum longus), often used to represent fast glycolytic
muscles, but is actually a mixed muscle type; TA (tibialis anterior), a larger muscle
consisting of mixed muscle fiber types; and finally FDB (flexor digitorum brevis), a
fast-glycolytic muscle located in the sole of the foot in mammals (Figure 7). Dualcolor western blot analysis confirmed that ssMyBP-C was expressed in all skeletal
muscles tested, as well as additional, large mixed muscles, such as the quadriceps
and the gastrocnemius (data not shown). Interestingly, fsMyBP-C was only
expressed in the EDL and TA skeletal muscles, but not the FDB nor SOL. This was
confirmed using traditional Western blot (Figure 8), using alternative antibodies
for fast- and slow-skeletal MyBP-C. Perhaps most surprisingly, fsMyBP-C was not
expressed in the FDB, which is considered a fast-type skeletal muscle, warranting
some caution when considering the nomenclature of the skeletal isoforms. Indeed,
earlier researchers also found the naming conventions to be unsatisfactory(Dhoot,
Hales, Grail, & Perry, 1985) There were no muscles tested with only fsMyBP-C,
though there are muscles in avian species that do exclusively express fsMyBP-C
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isoform in adulthood(Obinata & Shinbo, 1987). Overall, the expression
profile suggests ssMyBP-C is the baseline MyBP-C isoform necessary for normal
function throughout skeletal muscles, while fsMyBP-C expression may augment
particular muscle function. Notably, data on function of both isoforms are lacking.
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Figure 7. Expression profile of skeletal MyBP-C in FVB/N WT mice. Four
skeletal muscles were chosen to represent different types of muscles. Extensor
digitorum longus (EDL) and flexor digitorum brevis (FDB) are fast-type skeletal
muscles, soleus (SOL) is slow-type, and tibialis anterior (TA) is composed of both
slow- and fast-type skeletal muscles. fsMyBP-C is expressed in the EDL and TA,
while ssMyBP-C is expressed in all skeletal muscle tested.
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Figure 8. Skeletal MyBP-C expression quantified. Densitometry scan of
traditional Western blots validate expression profile demonstrated in dual-color
immunoblots (Figure 7).
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2.4 Summary: expression of MyBP-C isoforms is complex
Cardiac and skeletal MyBP-C isoforms are the predominant isoforms
expressed in cardiac and skeletal muscles, respectively. However, contrary to
commonly held preconceptions, MyBP-C isoforms often co-express with one another
in health and disease, cardiac and skeletal muscle (Figure 9). Both skeletal isoforms
(ssMyBP-C and fsMyBP-C) are expressed in the heart at the protein level: ssMyBP-C
is expressed in the atrial tissues of the heart and fsMyBP-C is upregulated in the
heart during disease conditions. The differential expression of ssMyBP-C and
fsMyBP-C in various skeletal muscles adds another layer of complexity. While
ssMyBP-C is expressed in every skeletal muscle we tested, fsMyBP-C is expressed
only within mixed skeletal muscles we tested. Further complications arise when one
considers that fsMyBP-C is not expressed in skeletal muscles that are considered
‘fast’-type (e.g. FDB), warranting some caution when considering the nomenclature.
It is worth noting that the naming convention of slow-skeletal, fast-skeletal, and
cardiac MyBP-C provides a degree of insight into where they are expressed.
Nevertheless, the expression profile of MyBP-C isoforms in cardiac and skeletal
muscles depicts a complex and nuanced contractile protein whose function
warrants detailed investigation. In particular, the expression of skeletal MyBP-C
practically begs the question: what are skeletal MyBP-C isoforms doing in the heart?
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Figure 9. Summary of skeletal MyBP-C Expression. MyBP-C are differentially
expressed in health and disease, cardiac and skeletal muscles. Therefore, the two
primary goals of my dissertation are to determine the function of fsMyBP-C in the
context of cardiac muscle and fsMyBP-C function in skeletal muscle.

CHAPTER FOUR
AIMS AND HYPOTHESIS
In the previous chapter, the combination of expression profile studies (Figure 7)
and previously published literature (Figure 9) (Dhoot & Perry, 2005; B. Lin et al.,
2013) clearly demonstrates the presence of skeletal isoforms of MyBP-C in the heart
in health and disease, contrary to what the names would suggest. The co-expression
of various MyBP-C isoforms prompted the question: What are the skeletal MyBP-C
isoforms doing in the heart? This question really then prompted another question:
What are the skeletal MyBP-C isoforms doing in skeletal muscles? The literature is not
particularly helpful in either regard, with only one study comparing the function of
all three MyBP-C (Colson et al., 2012), one study focusing specifically on fsMyBP-C
(M. Li et al., 2016), and few labs focused on ssMyBP-C (Ackermann & KontrogianniKonstantopoulos, 2013; Gurnett et al., 2010). The majority of the research on MyBPC is solely dedicated to cMyBP-C, from which my dissertation must draw certain
intuitive insights. However, this provides a fantastic opportunity to meticulously
compare and contrast fsMyBP-C, the least characterized isoform, with its slightly
better known relative, ssMyBP-C, and most well-known isoform, cMyBP-C.
Therefore, my objective is to comprehensively characterize the function of
fsMyBP-C in the context of cardiac and skeletal muscles.

42

43
Aim 1. Determine the steady-state function of fsMyBP-C in the cardiac system
Contrary to conventional wisdom, fsMyBP-C is demonstrated to be expressed
in the heart in murine models of heart failure. The function of fsMyBP-C in the
cardiac system is completely unknown, though distinct structural differences at the
N-terminal region of fsMyBP-C suggest functionally distinct regulation of muscle
contraction compared to cMyBP-C. In the case of the cardiac isoform, the N-terminal
region, from the C0 domain through the C2 domain, has been demonstrated to be
necessary and sufficient for the normal function of cMyBP-C. Therefore, I
hypothesized that fsMyBP-C N-terminal region up to the C2 domain
differentially regulates steady-state properties of cardiac muscle contraction.
To test this hypothesis, recombinant proteins were generated representing the Nterminal region of ssMyBP-C, fsMyBP-C, and cMyBP-C up to and including the C2
domain, and were thusly named ssC1C2, fsC1C2, and C0C2, respectively. These
recombinant MyBP-C N-termini were utilized for a battery of extensive tests based
primarily using cardiac contractile fibers and systems. The primary functional
experiment used was the steady-state fiber force-ATPase assay, capable of
simultaneously measuring force-pCa, force-ATPase, and force-stiffness
relationships, as well as rate of tension redevelopment (ktr). Actin cosedimentation
with ssC1C2, fsC1C2, and C0C2 was used to determine differential affinities and
capacities of MyBP-C isoforms to bind actin. These results will determine the
mechanism that may underlie differences in the regulation of steady-state function.
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Aim 2. Determine the dynamic function of fsMyBP-C in the cardiac system
Steady-state measurements capture detailed snapshots of a dynamic process.
Expression of fsMyBP-C in the heart may directly impact the dynamics of the heart
at the cellular level. Previous studies have suggested diseased hearts may revert to a
fetal gene programming to initially compensate for dysfunction(Rajabi, Kassiotis,
Razeghi, & Taegtmeyer, 2007), giving rise to re-expression of skeletal isoforms in
the heart. Given that cMyBP-C mutations are the leading cause of HCM, a condition
in which abnormally thickened ventricular walls may impair relaxation(Bonne et al.,
1998; Marston, Copeland, Gehmlich, Schlossarek, & Carrier, 2012), I hypothesized
that fsMyBP-C expression in cardiac cells would facilitate relaxation kinetics.
To test the effects of dynamic contraction on function, unloaded shortening was
examined in adult rat ventricular myocytes (ARVM) overexpressing full-length, myctagged ssMyBP-C, fsMyBP-C, and cMyBP-C. In addition, to elucidate potential
mechanisms that underlie dynamic contractile regulation, I applied computer
modeling previously used to simulate unloaded shortening of cardiac
cells(Campbell, Haynes, Kelsey Snapp, Nava, & Campbell, 2013; Kuo et al., 2014).
Computer modeling of unloaded shortening revealed thin filament activation as a
unifying mechanism behind both steady-state and dynamic contraction
experiments.
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Aim 3. Determine the steady-state function of fsMyBP-C in skeletal muscles
Expression of fsMyBP-C was specific to skeletal muscles with mixed fiber
types (Figure 7,8), in contrast to ssMyBP-C, which was expressed throughout all
skeletal muscles. This expression profile suggests fsMyBP-C exists to augment
skeletal muscle function in which it is expressed. The only study to compare
fsMyBP-C function with other MyBP-C isoforms suggests fsMyBP-C regulates by
restricting actin torsional dynamics (Colson et al., 2012). In the cardiac isoform,
actin binding has been demonstrated to directly promote thin filament
activation(Mun et al., 2014). Therefore, I hypothesized that fsMyBP-C regulates
thin filament activation in skeletal muscle system. To test this hypothesis, I
utilized the force-ATPase assay once to determine the skeletal muscle fiber function
of EDL muscles in a novel mouse model dubbed FSKO (Fast-Skeletal MyBP-C KnockOut) mice. EDL tissues were selected for three reasons: 1) EDL muscle normally
expresses fsMyBP-C. The absence of fsMyBP-C in FSKO mice would thus elicit more
pronounced skeletal muscle deficiencies in our functional assays 2) the fiber size of
EDL is ideal for use in force-ATPase assay, allowing for direct comparison with
force-ATPase assay 3) EDL is commonly used to represent ‘fast-type’ skeletal
muscles in the literature, allowing for comparisons with previously published
literature. Within the scope of my dissertation, I focused on the steady-state
functional aspects of the EDL of FSKO mice. However, it is worth noting additional
biochemical and functional characterization of FSKO mice are planned to fully
characterize this mouse model.

CHAPTER FIVE
FIBER FORCE-ATPASE ASSAY: N-TERMINAL REGION OF MYBP-C DIFFERENTIALLY
REGULATES MUSCLE CONTRACTION BY ACTIVATING THE THIN FILAMENT
5.1 Abstract
Skeletal and cardiac isoforms of MyBP-C are co-expressed in the heart during health
and disease, but how ssMyBP-C, fsMyBP-C and cMyBP-C differ in their regulation of
function is unknown. Previous studies demonstrated the necessity of the N-terminal
region of cMyBP-C, but each MyBP-C isoform is structurally distinct within this
region. Therefore, I hypothesized that the fsMyBP-C N-terminal region up to the
C2 domain differentially regulates steady-state properties of cardiac muscle
contraction. To test this hypothesis, I utilized the force-ATPase assay to determine
the function of recombinant proteins representing the critical N-terminal region of
MyBP-C (ssC1C2, fsC1C2, C0C2) in adult rat papillary muscle fibers (Figure 10),
which are sufficiently large for experiments and share homology with mice. The
results demonstrated that fsC1C2 and C0C2 increased Ca2+-sensitivity of force
development, as well as rate of tension redevelopment at submaximal Ca2+ levels,
suggesting that these N-terminal regions affect thin filament activation. While
ssC1C2 was not significantly different from controls, it was also not significantly
different from fsC1C2, suggesting this isoform may operate at an intermediary
modality and/or at even lower ranges of Ca2+.
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Figure 10. MyBP-C N-termini. Recombinant proteins representing the N-terminal
functional region of MyBP-C isoforms were generated up to, and including, the C2
domain. SDS-PAGE gels demonstrate the relative size and purity of each of the
MyBP-C recombinant proteins, encompassing the N-terminal region, up to and
including the C2 domain. The N-terminal fragments for ssMyBP-C, fsMyBP-C, and
cMyBP-C are named ssC1C2, fsC1C2, and C0C2, respectively. Previous studies have
demonstrated that this region is necessary and sufficient to recapitulate the
function of cMyBP-C.
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Figure 11. Papillary muscle fiber preparation. Papillary muscles were excised
from rats and permeabilized overnight. Muscles were trimmed down to size and tclipped. The fibers need to be this size to ensure penetration by recombinant
MyBP-C N-termini, as well as Ca2+.
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5.2 Results
5.2.1 Absolute Force: fsC1C2 and C0C2 promotes submaximal force
generation, and ssC1C2 trend suggests graded regulation
Similar studies have demonstrated cMyBP-C N-terminal fragments do not
alter maximal force production in the heart(Herron et al., 2006; Razumova et al.,
2008). At maximal activation states, permeabilized fibers are exposed to pCa 4.5, in
which Ca2+ levels are in excess of what is physiologically experienced by the
sarcomere. At pCa 4.5, maximal force generation was unchanged between fibers
incubated with ssC1C2, fsC1C2, and C0C2, reflecting the previous functional assays
using N-terminal fragments of cMyBP-C. However, our studies demonstrated that
fsC1C2 and C0C2 conferred significant force generation at submaximal Ca2+ levels to
different degrees (Figure 12). Interestingly, at most submaximal Ca2+ levels, ssC1C2
was not significantly different from controls nor other MyBP-C fragments,
suggesting ssC1C2 may operate at an intermediary step or at even lower Ca2+ levels
that are outside precision of the force-ATPase assay. Changes in submaximal force
generation suggested MyBP-C isoforms confer Ca2+-sensitization of force
development and/or regulate contraction via isoform-specific mechanisms.
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Figure 12. Force-pCa relationship. fsC1C2 and C0C2 promoted greater
submaximal, but not maximal, force generation. Graphs represented as mean ±
SEM, *p<0.05 vs. controls, **p<0.01 vs. controls, #p<0.05 vs. ssC1C2/fsC1C2, n=8-9
animals
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5.2.2 Force-pCa: fsC1C2 and C0C2 confers Ca2+-sensitization of force
development
To determine Ca2+-sensitivity of force development, submaximal force was
normalized to Fmax for each fiber. That is, maximal force was set to 1, and
subsequent submaximal activations of the fiber was normalized as a percentage,
providing a force-pCa curve (Figure 13). The force-pCa relationship reveals a
leftward shift in fsC1C2 and C0C2, indicating less Ca2+ is required to generate the
same amount of force. Conversely, a relative rightward shift would signify a
desensitizing effect. By convention, quantification of Ca2+-sensitivity was calculated
by determining the pCa50, which is the pCa value at which half-maximal force is
generated. This revealed greater pCa50 values, and thus Ca2+-sensitizing effects, by
both fsC1C2 and C0C2 compared to controls (Figure 13). Once again, the pCa50
value for ssC1C2 was between controls and fsC1C2/C0C2, further demonstrating
MyBP-C isoforms are not functionally equivalent and perhaps operated via unique
mechanisms.
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Figure 13. Ca2+-sensitivity of force development. Relative force-pCa curves
demonstrate fsC1C2 and C0C2 causes a leftward shift of the curve compared to
ssC1C2 and control. Quantification of pCa50 values demonstrate fsC1C2 and C0C2
increase Ca2+-sensitivity. Graphs represented as mean ± SEM, *p<0.05 vs. controls,
**p<0.01 vs. controls, #p<0.05 vs. ssC1C2/fsC1C2, n=8-9 animals.
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5.3.3 Stiffness-Force
Muscle fiber stiffness is simultaneously recorded during force recordings and are a
measure of bound cross-bridges. Therefore, stiffness would be indicative of whether
MyBP-C isoforms differentially regulated myosin binding to actin. At maximal levels,
stiffness is not significantly different between ssC1C2, fsC1C2, and C0C2, suggesting
the maximal number of XB that can be bound is not affected by MyBP-C N-termini
(Figure 14). When stiffness-force relationship is analyzed, one obtains a linear
relationship that is one measure of the duty ratio (Figure 14). The slope of which is
the amount of XB required to generate a certain amount of force. Quantification of
the slopes (stiffness/force) for the stiffness-force relationship reveals no significant
difference between groups. The closest to significance was fsC1C2’s trend towards
decreased stiffness/force values. Interestingly, two inferences can be made from
these observations. First, lack of regulation in stiffness suggests MyBP-C N-termini
may not be the primary regulators of myosin during contraction. This does not
preclude MyBP-C regulation of myosin during relaxation, MyBP-C regulation of
myosin in other conditions (e.g. post-translational modification, disease, etc.), nor
the possibility that the assay used lacked the necessary sensitivity. Thus, MyBP-C
isoforms may regulate contraction via interactions with actin. Second, the trend in
fsC1C2 observed suggested potential that fsC1C2 may regulate another aspect of
contractile function.
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Figure 14. Stiffness-force relationship. fsC1C2 and C0C2 trend towards
decreased stiffness, suggesting they may reduce the number of cross-bridges
required per unit of muscle contraction. However, changes were not significantly
different. Graphs represented as mean ± SEM, *p<0.05 vs. controls, **p<0.01 vs.
controls, #p<0.05 vs. ssC1C2/fsC1C2, n=8-9 animals.
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5.2.4 ATPase-Force
ATPase activity of muscle fibers during steady-state contraction was measured
using spectrophotometric recording of NADH conversion to NAD+, which is
enzymatically linked to ATPase activity of the myosin head. A previous trend in
fsC1C2 stiffness/force values suggested fewer bound XB are required to generate
force, prompting the hypothesis that fsC1C2 improves the efficiency of contraction.
If so, tension cost, or the amount of ATP required to generate force, would also be
reduced. To determine tension cost, the ATPase-force relationship was plotted for
individual fibers, generating a linear relationship whose slope would represent
tension cost (Figure 15). The steeper the slope, the higher the tension cost, and vice
versa. Analysis of ATPase-force relationship demonstrated fsC1C2 alone
significantly reduced tension cost compared to controls (Figure 15), suggesting
fsC1C2 regulation of contraction reduced the demand for ATP required to generate
force. None of the MyBP-C N’ fragments altered maximal ATPase activity. The results
presented thus far demonstrate MyBP-C differentially facilitates contraction, but not
necessarily a mechanism by which contraction is regulated. The literature points to
two powerful interaction partners, myosin and actin, but stiffness data (or lack
thereof) suggests MyBP-C N-termini may function via actin interactions. Differential
binding to thin filament proteins may also explain why fsC1C2 alone decreased
tension cost in the fiber studies, which is explored in the next chapter.
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Figure 15. fsC1C2 decreases tension cost. (left) ATPase-force relationship
(binned data) demonstrate energy expenditure per unit force. (right) Slope from
the ATPase-force relationship was then calculated to determine tension cost.
Graphs represented as mean ± SEM, *p<0.05 vs. controls, **p<0.01 vs. controls,
#p<0.05 vs. ssC1C2/fsC1C2, n=8-9 animals.
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5.2.5 Rate of tension redevelopment
I hypothesized the mechanism for MyBP-C regulation of contraction is due to
interactions between MyBP-C N-termini and actin, the rate of tension
redevelopment (ktr) of the muscle fibers was analyzed. The ktr is a measure of XB
kinetics and thin filament activation. To determine ktr values, a rapid release and
restretch maneuver is applied to the muscle fibers at the end of contraction. This
maneuver breaks XB by physically disrupting actomyosin interactions by rapidly
shortening the muscle fiber sarcomere length. Subsequently, the restretch back to
the original sarcomere length will allow for myosin to once again bind to actin, in
which the rate of force redevelopment, ktr, can be measured (Figure 16). Since XB
interactions have been broken, the primary affecter of ktr is the activation state of
the thin filament. Results demonstrate that at maximal activation levels, ktr is
unchanged between groups (Figure 17). However, at submaximal activation levels
(pCa 6), fsC1C2 confers higher ktr relative to controls, and C0C2 confers greater ktr
relative to both controls and ssC1C2, indicating MyBP-C N-termini have graded
capacity to activate the thin filament (C0C2 > fsC1C2 > ssC1C2). Interestingly, these
results correlate with the force generation data at their respective activation levels
(Figure 17). Specifically, Fmax and ktr (pCa 4.5) demonstrate no change between all
groups, but both fsC1C2 and C0C2 demonstrate increased submaximal force and ktr
(pCa 6), suggesting thin filament activation is how MyBP-C differentially regulates
contraction at these ranges of Ca2+.
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Figure 16. Rapid release and restretch maneuver. By rapidly shortening the
sarcomere to 80%, attached cross-bridges are broken. The following restretch
back to resting sarcomere length allows the detached cross-bridges to re-attach,
thus regenerating force. The rate of tension redevelopment (ktr) is a measure of
thin filament activation, because the state of thin filament is the primary
determinant after cross-bridges are removed.
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Figure 17. fsC1C2 and C0C2 increase cross-bridge cycling kinetics at
submaximal Ca2+ levels. The rate of force redevelopment (ktr) was determined
following a rapid release and restretch maneuver (Figure 16). Graphs represented
as mean ± SEM, *p<0.05 vs. controls, **p<0.01 vs. controls, #p<0.05 vs.
ssC1C2/fsC1C2, n=5-9 animals.
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Control

+ssC1C2

+fsC1C2

+C0C2

pCa50

5.2 ± 0.46

5.47 ± 0.06

5.71 ± 0.06*

5.6 ± .16*

Tension
Cost

4.94 ± 0.45

3.95 ± 0.30*

2.7 ± .40**

4. 1 ± 0.36*

ktr (pCa 6)

1.97 ± 0.98

3.70 ± 1.81

4.23 ± 0.50*

6.22 ± 0.53***

Force
(pCa 6)

0.62 ± 0.32

3.27 ± 1.70

9.48 ± 2.40**

9.50 ± 2.09**

#

Table 2. Effects of MyBP-C N-termini as determined by Force-ATPase assay. Units
for tension cost (pmol/s/fiber volume), ktr (s-1), force (mN/mm2). Values are
mean ± SEM. ***p<0.0001, **p<0.01, *p<0.05 vs. control; #p<0.05 vs. ssC1C2
(n=5-9 animals)
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5.2.6 Changes in steady-state function were not due to changes in ionic
strength nor presence of random exogenous protein
Ionic strength has been previously demonstrated to alter steady-state
myofilament properties (April, Brandt, Reuben, & Grundfest, 1968; Iwamoto, 2000;
Julian & Moss, 1981; Martyn & Gordon, 1988; Thames, Teichholz, & Podolsky, 1974).
In the present study, recombinant proteins were dialyzed in PBS and subsequently
lyophilized. Briefly, this means the recombinant proteins in solution were freezedried (see Chapter 12). The lyophilized recombinant proteins (at 10 µM) were
reconstituted with relaxing or preactivation solution prior to the beginning of the
fiber assays. It was possible that the residual salts that remained after the
lyophilization, however minimal, may influence functional results by increasing
ionic strength. A second possible source of aberrant results may arise from the
presence of any random large protein. That is to say, the results were from random
large proteins interacting with the myofilament and not due to specific interactions
of MyBP-C fragments. Therefore, to determine whether the additional salts from the
lyophilization process was sufficient to induce changes in force production, stiffness,
and ATPase activity, I generated recombinant proteins (ssC1C2, fsC1C2, and C0C2)
dialyzed in PBS and diH2O, followed by lyophilization and reconstitution in relaxing
and preactivation solutions to a concentration of 10 µM (the concentration used in
the previously presented fiber studies) and 30 µM (Figure 18). Because proteins
dialyzed in diH2O would not have residual salts, these recombinant proteins would
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not contribute to ionic strength. An additional control, chicken egg albumin, was
processed in parallel with MyBP-C proteins to control for the presence of a random
large protein in the system. Chicken egg albumin was chosen as a control, because
its size is approximately the average of the MyBP-C fragments (~45 kDa).
Baseline activation data for fibers were first gathered in the absence of
recombinant proteins, followed by incubation with recombinant proteins and a
subsequent maximal activation. The differences between the second activation and
initial activation were calculated as ΔForce, ΔStiffness, and ΔATPase activity (Figure
19). Results demonstrate no significant changes in these functional parameters,
regardless of whether 10 µM recombinant proteins were dialyzed in PBS and diH2O.
This suggests that the functional studies conducted with recombinant proteins at 10
µM were not influenced significantly by increases in ionic strength. Furthermore, the
observed changes in function in previous results (e.g. increase in force) are opposite
of what one would predict if ionic strength were increased, as increases in ionic
strength have been previously demonstrated to depress force.
To determine whether even higher concentrations of recombinant proteins
dialyzed in PBS can be used, fibers were also tested in the presence of 30 µM
recombinant proteins. Results demonstrate that even when recombinant proteins
were lyophilized and reconstituted to a final concentration of 30 µM, the contribution
of the residual salts to ionic strength were not sufficient to significantly alter the
steady-state functional parameters, with the exception of fsC1C2 dialyzed in PBS,
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which drastically reduced force production (Figure 19). Because recombinant
fsC1C2 dialyzed in PBS was at such a low concentration initially, this required
significantly larger volume to be lyophilized to reach a final concentration 30 µM.
Thus, the lyophilization process drastically increased the quantities of residual salts
in the lyophilized form. In support of this, fibers incubated with comparable
quantities of lyophilized salts also reflected the decrease in force production
observed in fsC1C2 in PBS (30 µM), but fibers incubated with fsC1C2 in diH2O at 30
µM did not alter functional parameters. Thus, a high concentration is not
recommended when using low-yield recombinant proteins dialyzed in PBS. Even
slight variations in initial concentrations of recombinant proteins can greatly amplify
the effects of ionic strength or possibly protein stability. Given these results, careful
consideration must be given to the process of generating recombinant proteins to
ensure the validity of assays where they are used in the future.
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Figure 18. Protocol to determine whether changes in ionic strength affected
force development. Papillary muscles were excised and initially activated to
obtain baseline force, stiffness, and ATPase measurements, followed by incubation
with MyBP-C N-termini dialyzed in PBS or diH2O (10 and 30 µM). This was followed
by a second activation and changes in parameters were determined.
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Figure 19. Ionic strength changes do not alter force production at 10 µM.
Chicken egg albumin (Alb), ssC1C2 (slow), fsC1C2 (fast), C0C2 (cardiac) dialyzed
in PBS or diH2O were incubated with muscle papillary fibers using the protocol in
Figure 18. (left) No changes were detected when 10 µM of proteins were used,
demonstrating ionic strength did not affect force-ATPase data. (right) There were
also no difference using 30 µM of proteins, with the exception of fsC1C2 dialyzed
in PBS (fast PBS 30), suggesting that the ionic concentration was sufficiently
increased to cause a significant depression in force. This was due to higher
concentration of salts, as demonstrated by an included group of just the salts (PBS
30). Graphs represented as mean ± SEM, *p<0.01, n=3-9
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5.3 Discussion
MyBP-C N-termini have graded ability to regulate muscle fiber contraction
The primary aim of the experiments in this chapter is to determine the
steady-state regulation of contraction by the N-terminal region of fsMyBP-C
(fsC1C2) in the context of the heart, because skeletal MyBP-C isoforms may be
present in cardiac muscles (Figure 6). In addition, I compared the function of
fsC1C2 to the N-terminal region of ssMyBP-C and cMyBP-C, the latter of which had
been previously demonstrated to increase Ca2+-sensitivity and submaximal force
generation (Herron et al., 2006; Razumova et al., 2008; Razumova et al., 2006;
Walcott, Docken, & Harris, 2015). Due to the distinct structural differences between
MyBP-C isoforms within the N-terminal region, I had hypothesized each isoform has
distinct regulatory profiles. The N’ fragments (ssC1C2, fsC1C2, and C0C2) were
applied to cardiac papillary muscle fibers in the force-ATPase assay.
The fiber force-ATPase assay is an incredibly powerful, albeit timeconsuming, experimental assay, capable of measuring several parameters
simultaneously from a single mounted fiber. In reality, the assay is an amalgamation
of several experiments that analyze multiple relationships including force-ATPase,
force-pCa, stiffness-force, and ktr-pCa. Furthermore, modifications can be easily
made to experiment protocols to test for additional effects that were not tested for
in the present study. Here, permeabilized rat papillary muscle fibers were incubated
with 10 μM ssC1C2, fsC1C2, and C0C2, and analyzed the resultant relationships

between Force,

Ca2+
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(pCa), ATPase activity, stiffness, and ktr (Figure 12 - 17).

The presence of exogenous N-terminal fragments had no effect on maximum force
development and fiber stiffness at pCa 4.5 (Figure 12, 14); both serving as
measures of the number of attached cross-bridges. However, as reported previously
(Razumova et al., 2008), exogenous C0C2 increased Ca2+ sensitivity of force
development as evidenced by a leftward shift in the normalized force-pCa curve and
thus a significant increase in the pCa50 (Figure 13). This, too, was the case for
fsC1C2, but not ssC1C2, strongly suggesting the various MyBP-C N-termini are not
functionally equivalent. The differences between fsC1C2 and C0C2 versus ssC1C2
are further emphasized by analyzing kinetic parameters of cross-bridge cycling
(Figure 17).
Previous studies have demonstrated cMyBP-C can activate the thin filament
independently of Ca2+ (Mun et al., 2014), which may underlie its ability to promote
submaximal force (Herron et al., 2006) (Figure 12). To determine whether this may
be a unifying mechanism by which fsC1C2 and C0C2 regulate contraction, we
applied a rapid release and immediate restretch of the fiber’s length to detach crossbridges. As expected, at maximal activation (pCa 4.5), ktr was not different than
control for all N-terminal fragments (Figure 17 and Table 2). However, at
submaximal Ca2+ levels (pCa 6.0), both fsC1C2 and C0C2 increased ktr relative to
controls, suggesting that, in addition to Ca2+-sensitization of the thin filament, these
fragments can also modulate cross-bridge kinetics by activating the thin filament in
a Ca2+-dependent manner to promote submaximal force generation (Figure 12).
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The effect of MyBP-C N-termini is summarized in Online Video 2
(https://vimeo.com/148663470). Interestingly, ssC1C2 was not significantly
different from control nor fsC1C2, suggesting the slow-skeletal isoform may
regulate function at an intermediate modality or at even lower Ca2+ levels. My
working theory is that ssC1C2 regulates contraction at low Ca2+, while fsC1C2
regulates function at high Ca2+, while C0C2 regulates contraction over the full
spectrum of Ca2+.
Comparison to the literature provides unique insight into molecular
mechanisms by which MyBP-C regulates contraction
The objective of this experiment was to parse out differences between
ssC1C2, fsC1C2, and C0C2, with the latter fragment acting as an additional control in
order to compare it with the literature. It is important to note that this study utilized
a concentration (10 µM) that was much higher than some previously published
studies using cMyBP-C fragments (Hofmann, Hartzell, & Moss, 1991; Previs et al.,
2012; A. Weith et al., 2012; A. E. Weith et al., 2012), comparable to others
(Razumova et al., 2008; Razumova et al., 2006; Witayavanitkul et al., 2014), and
much lower than others (Herron et al., 2006). When comparing results with
previously published research, one must consider the variability in concentrations
used (from nM concentrations – 80 µM), species used (mouse, rat, chicken, human),
exogenous tags (biotin, cMyc, His, TEV-cleaved), and experimental assays (laser-trap
orbital, motility assay, force-ATPase). Further complicating matters is the fact that
within the same group, different species of recombinant cMyBP-C were used in
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different systems (e.g. mouse cMyBP-C fragment in chicken skeletal muscle)(A.
Weith et al., 2012; A. E. Weith et al., 2012). That being said, there were many
similarities and differences between the present results and previously published
literature, some of which are worth highlighting for discussion.
As previously mentioned, MyBP-C promotion of Ca2+-sensitivity and
submaximal force generation from our results is in agreement with similar studies
in the literature (Herron et al., 2006; Razumova et al., 2008; Razumova et al., 2006),
though some disagreement exists within the literature (Kulikovskaya et al., 2003).
The latter study did conduct its experiments at a longer SL, which has been
demonstrated to eliminate the effect of cMyBP-C(Witayavanitkul et al., 2014),
suggesting cMyBP-C contributes to length-dependent activation (Cazorla &
Lacampagne, 2011; de Tombe et al., 2010; Kumar et al., 2015; Mamidi, Gresham,
Verma, & Stelzer, 2016). Whether cMyBP-C is physically altering myofilament
properties to activate LDA or transducing a signal to its myofilament neighbors
requires further analysis in future studies.
One particular study was of particular interest for comparison
(Witayavanitkul et al., 2014), because it was the closest to the present study and the
similarities and differences yielded novel insights into my own data. In the
aforementioned study, the fragment used is known as hC0C1f, which is a human
cMyBP-C fragment that is cleaved after a major cardiac insult (Govindan et al., 2013;
Govindan et al., 2012). This cMyBP-C fragment demonstrated reduction in Fmax, as
well as other pathogenic qualities, in contrast to observations in the present study
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and other studies that demonstrate no change in Fmax, but increases in submaximal
force (Herron et al., 2006). Importantly, the source of this fragment, hC0C1f, is from
a pathogenic source and cleaves at a critical region within the M-motif, which has
been demonstrated to be vital for cMyBP-C function(Razumova et al., 2008), though
not necessarily binding (Shaffer, Kensler, & Harris, 2009). Specifically, the first 17
amino acids of the M-motif are absolutely necessary which is absent in the hC0C1f
(Witayavanitkul et al., 2014). Therefore, the hC0C1f fragment would have been able
to bind to the thin filament, but due to the lack of this critical region in the M-motif,
hC0C1f also was unable to promote force generation. One reason why the present
study used N-terminal fragment that included up, and including, the C2 region was
because of the numerous studies that demonstrated that this entire N-terminal
region was necessary to recapitulate cMyBP-C function and that missing pieces were
only able to partially regulate contraction. Thus, the hC0C1f acts as competitive
inhibitor of force generation: it binds to the thin filament, but lacks the critical
region of the M-motif and C2 domain that are required to help promote force
generation.
But the hC0C1f also promoted ktr and Ca2+-sensitivity, reflecting our results
and much of the literature. How does it do so, considering it is missing a specific
region that I just mentioned was critical to cMyBP-C function? The answer lies
within the data set itself: promotion of ktr implicates the hC0C1f as an agent capable
of influencing thin filament activation, which is closely related to Ca2+-sensitivity.
This suggests that the fragment hC0C1f, while lacking the region critical for force
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generation, still has the critical regions responsible for actin binding and thin
filament activation. When considering the results from the present study and
Witayavanitkul et al. 2014, there appears to be a division of labor between the
domains within the N-terminal region of MyBP-C: particular domains are
responsible for certain aspects of MyBP-C function and/or binding to different
locations on the thin filament. Overall, these results suggested that MyBP-C Ntermini interaction with the thin filament underlies its differential regulation, and
the next chapter expounds on my working theory through experiments that
examine actin binding.

CHAPTER SIX
ACTIN BINDING STUDIES
6.1 Abstract
The fiber force-ATPase assays from Chapter Five demonstrated that the MyBP-C Nterminal fragments are not functionally equivalent. C0C2 and fsC1C2 had
significantly greater activation of the thin filament and submaximal force
production, while ssC1C2 only trended towards significant regulation of contraction.
These results suggested that MyBP-C binding to the thin filament may underlie
functional regulation of steady-state contraction. To investigate MyBP-C binding
effects, three experiments with these recombinant proteins were employed: 1) actin
cosedimentation 2) 3D reconstructions 3) TPA assays. My results with the actin
cosedimentation suggests that fsC1C2 and C0C2 have greater binding capacity to
bind actin. In support of this, 3D reconstructions of actin binding demonstrate
fsC1C2 and C0C2 bind two subdomains of actin (SD1 and SD2), while ssC1C2 bind
only one subdomain (SD1). Interestingly, SD1 is the binding site for myosin, and
thus may be why ssC1C2 is unable to regulate contraction at higher Ca2+. However,
at low Ca2+, 3D reconstructions of thin filaments demonstrated C0C2 and ssC1C2
had greater capacity to activate the thin filament than fsC1C2. Finally, TPA assays
demonstrated each MyBP-C uniquely regulated actin torsional movement, with
C0C2 and ssC1C2 exhibiting increased resilience relative to fsC1C2.
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6.2 Results
6.2.1 Actin binding – cosedimentation assays
To assess the binding affinities and capacities of MyBP-C N-termini to actin, I
applied actin cosedimentation assays (Figure 20) in which increasing
concentrations of ssC1C2, fsC1C3, and C0C2 (1-30 µM) were incubated with F-actin
(5 µM) and rapidly spun down. Combined data from high-speed cosedimentation of
MyBP-C fragments (Figure 21) revealed affinity (Kd) to actin (Table 3) and binding
capacity (Bmax) for each isoform. Previous reports have independently determined
the Kd and Bmax values for C0C2 (Shaffer et al., 2009), and comparisons with our
C0C2 cosedimentation results reveal similar binding values (Shaffer et al. 2009: Kd
13.7 ± 5.5 and Bmax = 0.92 ± 0.11). Interestingly, comparisons with the ssC1C2 and
fsC1C2 reveals unique actin binding profiles. The ssC1C2 binding curve yielded the
lowest Kd, suggesting significantly higher binding affinity relative to fsC1C2 and
C0C2. However, fsC1C2 and C0C2 exhibited approximately twice the Bmax value
relative to ssC1C2, suggesting greater binding capacity. This last result suggested
fsC1C2 and C0C2 may bind have two binding sites on actin, while ssC1C2 only had
one. However, cosedimentation assays alone could not determine whether binding
was the case. Therefore, we next collaborated with the lab of Dr. Roger Craig to
confirm binding capacity and more specifically determine localization of binding.
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Figure 20. Cosedimentation binding data for C0C2. A representative high
speed cosedimentation assay. (left) C0C2 (1-30µM) was mixed with 5 µM F-actin
and spun for 30 min. at 390,000 x g. (right) Quantification of binding curves
required comparison with standard curve that was run on each gel, consisting of
varying known molar ratios of C0C2 to actin. This was done for multiple
experiments using ssC1C2, fsC1C2, and C0C2.
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Figure 21. fsC1C2 and C0C2 have higher F-actin binding capacity. (left)
Summary data of actin cosedimentation data demonstrates fsC1C2 and C0C2 has
approximately twice the Bmax (binding capacity) of ssC1C2 (see Table 3). (right)
actin monomer diagram showing the four subdomains. The higher capacity
suggests possible binding to twice the number of actin subdomains. (n=6-12)
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MyBP-C isoform

n

Kd (µM)

Bmax (mol/mol actin)

ssC1C2

7

2.08 ± 0.76*

0.45 ± 0.15*

fsC1C2

6

10.51 ± 4.75

1.14 ± 0.25

C0C2

12

16.62 ± 2.88

1.11 ± 0.12

#

Table 3. Summary of dissociation constants (Kd) and molar binding ratios (Bmax)
calculated from binding of recombinant MyBP-C N-terminal proteins to F-actin.
Values are mean ± SEM. (p<0.05 significant change compared *vs. C0C2 #vs.
fsC1C2)
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6.2.2 Actin binding – 3D reconstructions
In collaboration with Dr. Ji Young Mun and Dr. Roger Craig, we investigated
the effects of ssC1C2, fsC1C2, and C0C2 on actin binding. While the ideas and
conclusions made in this section are my own, the figures in this section represent
the work of Dr. Mun and are reproduced here with permission.
In the previous cosedimentation assay, the Bmax value for fsC1C2 and C0C2
were approximately twice that of ssC1C2, suggesting the fsC1C2 and C0C2 has twice
the binding capacity as ssC1C2. Thus, fsC1C2 and C0C2 may bind to twice as many
locations on actin as ssC1C2. Specifically, fsC1C2 and C0C2 may bind to two
subdomains on actin, while ssC1C2 only binds to one subdomain. To visualize
binding interactions of recombinant MyBP-C N-termini, we utilized 3D
reconstructions of computer-aligned actin filaments decorated with ssC1C2, fsC1C2,
and C0C2. Both filamentous actin (F-actin) and reconstituted thin filaments were
decorated with MyBP-C N-terminal fragments and imaged by negative stain electron
microscopy (EM) at low Ca2+ (Figure 22). The increase in filament diameter for Factin in the presence of each MyBP-C N-termini confirms the fragments’ ability to
bind actin (data not shown). Similarly, all fragments bound to reconstituted thin
filaments, consisting of actin (A), tropomyosin (Tm), and troponin (Tn) (Figure 23).
We propose reconstituted thin filaments represents the state of the thin filament at
low Ca2+, because Tn and Tm are present on the actin filament, blocking the myosin-
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binding site. Conversely, F-actin alone represents the state of the thin filament at
high Ca2+, because the myosin-binding sites on actin are not obscured.
In agreement with the actin cosedimentation assay results, 3D
reconstructions indicate fsC1C2 and C0C2 decoration on the actin filament creates a
greater space-filling density (Figure 22), correlating roughly with actin subdomains
1 (SD1) and subdomain 2 (SD2). In contrast, ssC1C2 decoration creates a much
smaller density that correlates with subdomain 1 of actin. Interestingly, subdomain
1 of actin is also known to be the primary binding site for the myosin S1 region. At
higher Ca2+, myosin S1 region would compete for the SD1 region and displace
ssC1C2, which would explain why its regulatory function is limited at higher Ca2+.
However, because fsC1C2 and C0C2 bind to both SD1 and SD2 of actin, these
isoforms are capable of continued regulation of contraction at high Ca2+.
Previous studies reported that binding of cMyBP-C N-terminal fragments
(C0C2, C0C3) to thin filaments, in the absence of Ca2+, shifts Tm from the “blocked”
position to “closed” position, which then favors weak cross-bridge formation (Mun
et al., 2014). 3D reconstruction of the thin filament was used to determine the
degree of Tm shift by ssC1C2, fsC1C2, and C0C2. To visualize relative difference in
MyBP-C-mediated Tm shift, the position of Tm in the blocked and closed positions
are indicated by the red and green helices, respectively (Figure 23). Densities
representing Tm position demonstrate that all MyBP-C N-terminal fragments can
shift Tm position at least from the blocked to closed position, and thus activate the
thin filament in a manner similar to that initiated by Ca2+. However, C0C2 and
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ssC1C2 mediated a greater Tm shift compared to the closed Tm position (green
helix), while fsC1C2 only shifted Tm equal to the closed position. Furthermore, C0C2
had a greater capacity to shift Tm relative to ssC1C2, revealing a graded thin
filament activation capacity (C0C2 > ssC1C2 > fsC1C2) at low Ca2+. The unique
capacity of each isoform to shift Tm strongly suggests differential thin filament
activation may be one mechanism by which MyBP-C isoforms regulate contraction
at low Ca2+.
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Figure 22. 3D reconstruction of F-actin and MyBP-C visualize binding sites. Factin were decorated with MyBP-C N-termini and computer-assisted alignment of
EM images was used to create 3D reconstructions. (left) Actin filament alone was
used as a reference for modeling with MyBP-C N-termini, and the actin monomer
diagram was overlaid to identify approximate locations of subdomain (SD) 1 – 4.
Densities representing ssC1C2 (red circle), fsC1C2 (blue circle), and C0C2 (black
circle) are highlighted. Original image courtesy of Dr. Ji Young Mun and Dr. Roger
Craig.
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Figure 23. 3D reconstructions of reconstituted thin filament and MyBP-C
demonstrate thin filament activation. Reconstituted thin filament consist of
actin, tropomyosin (Tm), and troponin (Tn). The red helix is the Tm in the blocked
position, when it is blocking the actin SD1 where myosin binds. The green helix is
Tm in the closed position, with actin SD1 exposed. Decoration with ssC1C2 and
C0C2 are able to shift Tm beyond the closed position, while fsC1C2 shifted Tm to
the closed position. Original image courtesy of Dr. Ji Young Mun and Dr. Roger
Craig.

6.2.3 Actin binding – TPA assays
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In collaboration with Dr. Brett Colson and David Thomas, we investigated the
effects of ssC1C2, fsC1C2, and C0C2 on actin dynamics. While the ideas and
conclusions in this section are my own, the figures in this section represent the
work of Dr. Brett Colson and are reproduced with permission.
To test whether MyBP-C isoforms alter the nature of interaction with actin at
low and high Ca2+, we utilized time-resolved phosphorescence anisotropy (TPA) to
determine how MyBP-C isoforms influence the torsional dynamics of actin filaments
(Figure). We propose that the F-actin model allows representation of the state of
the thin filament at high Ca2+, when the myosin-binding sites on actin are exposed.
More importantly, TPA assay provides data on actin dynamics, which becomes
important when considering actin filaments are not stationary players during
contraction: the helical coils of actin filaments are rapidly twisting, with variable
amplitude and rates of torsion. Differential actin binding by the N-terminal region of
MyBP-C isoforms would uniquely restrict the amplitude and rates of actin,
potentially in a manner to assist or resist myosin binding.
To determine intrafilament torsional motions with the TPA assay, actin
filaments were uniformly labelled at Cys374 with a phosphorescent dye (Figure
24A). MyBP-C N-termini decreased amplitude of labelled actin TPA decay (Figure
24B), and all three MyBP-C N-termini had similar effects in increasing final
anisotropy at low and high occupancy (Figure 24C). TPA amplitude was greatly
reduced by all three MyBP-C N-termini (Figure 24D), with C0C2 having the greatest
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amount of restriction on the amplitude of actin motion, followed by fsC1C2 and
ssC1C2. Interestingly, while C0C2 increased the rate of actin torsional dynamics,
fsC1C2 decreased this torsional rate (Figure 24E and Table 4). Because C0C2
restricted the range of motion of actin, the rates of torsion were increased as
expected, a trend also observed in ssC1C2-bound actin. Both increased rate and
decreased amplitude is indicative of an actin filament whose movement is
constrained, but is moving very rapidly within its limitations by ssC1C2 and C0C2.
However, fsC1C2 reduced both amplitude and rate of actin filament torsion,
suggesting fsC1C2 binding may result in an actin filament that is less dynamic and
have a reduced effect on the resilience of the actin filament. Resilience is an
indicator of stored elastic energy, and is determined by Rate/Amplitude (A. Y. Lin et
al., 2012). We observed ssC1C2 and C0C2 confer higher resilience relative to fsC1C2
(Figure 24F), and higher resilience has been previously shown to increase tension
cost (Jones et al., 1999). Interestingly, our fiber studies also demonstrate ssC1C2
and C0C2 exhibit higher tension cost relative to fsC1C2 (Figure 15), suggesting
fsC1C2 reduces tension cost through isoform-specific regulation of actin resilience.
Furthermore, fsC1C2 also reduced tension cost relative to control fibers, suggesting
fsC1C2 is an active, rather than passive, participant in the regulation of actin
resilience. The unique restrictions on actin torsional motion by each MyBP-C
isoform all indicate unique binding interactions with actin.
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Figure 24. MyBP-C differentially regulates actin torsional dynamics. Actin
binding was determined by time-resolved phosphorescence anisotropy (TPA) and
actin co-sedimentation assays. 1 µM of MyBP-C N-termini binding to actin alters
actin amplitude, rate of twisting, and resilience. (A) Schematic of intrafilament
torsional dynamics. (B) MyBP-C N-termini results in the decay of ErIA-actin (black
trace) compared to actin alone (grey trace) and (C) Dependence of final anisotropy
of C0C2, fsC1C2, and ssC1C2 on actin binding. (D) Final anisotropy of actin as a
function of the fraction bound to MyBP-C N-termini. All three MyBP-C N-termini
restricted the amplitude of actin torsional dynamics, but C0C2 significantly
reduced the amplitude relative to fsC1C2 and ssC1C2. (E) fsC1C2 decreased the
rate of actin torsion, but C0C2 increased the rate of actin torsion. (F) Maximal
relative resilience was measured as rate/amplitude compared to actin alone. C0C2
and ssC1C2 both significantly increased resilience, but fsC1C2 did not. Source data
shown in Table 4. Original image courtesy of Dr. Brett Colson and Dr. David
Thomas.
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MyBP-C
Isoform

φ1

φ2

r1

r2

r∞

None

182±10

26±2

0.042±0.002

0.036±0.002

0.035±0.005

C0C2

221±18

19±3

0.014±0.002*

0.030±0.003

0.079±0.006*

fsC1C2

326±19*

21±3

0.023±0.002*

0.021±0.002*

0.062±0.008*

ssC1C2

201±16

27±3

0.020±0.004*

0.029±0.001*

0.059±0.005*

Table 4. Effect of Saturating Concentration of MyBP-C N-terminal regions on the
Parameters of Actin TPA Decay. Values are mean ± SEM (n > 5). (*p<0.05
significant change compared to control)

86
6.3 Discussion
The mechanism by which MyBP-C isoforms regulate at low and high Ca2+ is
explored in this section. These results collectively demonstrate distinct actin
profiles by each MyBP-C N-termini, suggesting its functional role is rooted in
changes at the molecular level. The higher affinity (Kd) and lower capacity (Bmax) of
ssC1C2 to actin (Figure 21 and Table 3) may explain why ssC1C2 only activates
during the early stages of contraction at low Ca2+ (Figure 23), while modestly
regulating contraction at higher Ca2+, as observed in fiber studies (Figure 17).
Conversely, fsC1C2 and C0C2 had approximately twice the capacity to bind to actin,
suggesting these isoforms may bind to an additional site on actin (Figure 22). This
additional interaction may confer the greater ability to regulate contraction at
higher Ca2+ levels later in the contraction process. Indeed, 3D reconstructions of Factin demonstrates fsC1C2 and C0C2 interact with actin SD1 and SD2, while ssC1C2
only binds SD1. Assuming binding to the same actin monomer, this makes perfect
sense why ssC1C2 is no longer able to regulate contraction at later stages of
contraction, because actin SD1 is also a well-known myosin-binding site for the
myosin S1. As the contractile process progresses, additional myosin S1 will directly
compete with MyBP-C for actin SD1. Therefore, the lone actin-binding site for
ssC1C2 will be occupied while fsC1C2 and C0C2 can still regulate contraction during
these later stages of contraction via its interaction with SD2.
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Some questions arise when considering the other actin subdomains and
myosin interaction with actin. First, why does MyBP-C not bind to actin subdomains
3 and 4? Second, how might myosin binding to actin SD1 disrupt fsC1C2 and C0C2?
The literature provides clues that may answer both in the future. First, MyBP-C is
unlikely to bind to SD3 and SD4: these subdomains are thought to be responsible for
intrafilament interactions (Chapter Two)(Kabsch et al., 1990). The helical structure
of F-actin requires tight interactions between its actin monomers, which provides a
major groove in which another helical thin filament, Tm, and SD3 and SD4 mediate
that function.
Second, myosin would certainly compete with fsC1C2 and C0C2 binding to
actin SD1, though evidence of myosin binding to other regions of actin indicate
myosin S1 interaction may actually be further away from where fsC1C2 and C0C2
bind to actin. Our data does not preclude MyBP-C or myosin binding on different
sites on multiple actin, nor binding to inter-subdomain pockets. While SD1 is
thought to be the primary binding site for myosin, an unresolved loop region of
myosin head is known to interact with the SD1 and SD3 junction (Milligan, 1996;
Milligan et al., 1990). However, this junction is further away from SD2 and less likely
to interfere with fsC1C2 and C0C2 binding to SD2 (Figure 21), though myosin S1
and MyBP-C are still in close proximity and our data does not preclude this
possibility. Furthermore, myosin S1 and MyBP-C may interact on different actin
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monomers along the F-actin filament and not necessarily be in direct competition.
Interestingly, the actin-binding affinities of MyBP-C N-termini versus myosin S1
have not been compared. As an aside, it may very well be that MyBP-C N-termini
have a higher affinity for actin SD1 compared to myosin and its role is to block
actomyosin interaction. This is unlikely, as fiber studies performed with fragments
in the present study and elsewhere would have shown significant suppression of
force production, especially in light of the high concentrations used. Furthermore,
even if this was the case in vivo, this effect would be localized to every third myosin
within the C-zone and not throughout the sarcomere.
MyBP-C isoforms exhibit different capacity to shift Tm (C0C2 > ssC1C2 >
fsC1C2) (Figure 23). Remarkably, ssC1C2 and C0C2 were able to shift Tm position
beyond the ‘closed’ position, suggesting the greater capacity to shift Tm by C0C2 and
ssC1C2 at low Ca2+ is important for initiating the contraction process. At higher Ca2+,
fsC1C2 and C0C2 are the predominant activators of the thin filament (Figure 17),
suggesting these isoforms are responsible for regulation in the later stages of
contraction. Increased thin filament activation by fsC1C2 and C0C2 would expose
the myosin-binding site on actin, promoting actomyosin interaction and thus crossbridge duration. This supports the previous research that suggests MyBP-C
contributes to the maintenance of longer cross-bridge duration (Palmer et al., 2011),
and may thus explain why we observe greater submaximal force production (Figure
12). Enhancement of cross-bridge duration almost assuredly rests on the ability of
MyBP-C to regulate actomyosin interaction via direct interaction.
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In support of this, MyBP-C/actin binding confers structural stability to actin
akin to myosin/actin binding during cross-bridge formation (Figure 24), suggesting
maintenance of actin resilience structural stability may be necessary to facilitate
optimal force production, which is often disrupted in disease states (A. Y. Lin et al.,
2012). MyBP-C stabilization of actin may therefore be an important aspect of its role
at high [Ca2+], and provides evidence of a so-called “C-bridge,” in which MyBP-C
binding to actin creates a second thick-to-thin filament interaction to modulate the
cross-bridge. This MyBP-C/actin interaction may compete with myosin for binding
site or place a load on actin, thus limiting contractility (Walcott et al., 2015; A. Weith
et al., 2012; A. E. Weith et al., 2012). Alternatively, MyBP-C may place a load on
myosin, limiting cross-bridge formation via a tethering mechanism (Barefield &
Sadayappan, 2010; Kampourakis, Yan, Gautel, Sun, & Irving, 2014). Indeed, recent
studies show MyBP-C may favor myosin binding at high [Ca2+] (Kampourakis et al.,
2014; Previs et al., 2016), further highlighting the Ca2+-dependent effects of MyBP-C.
Whether MyBP-C acts on myosin or actin at high [Ca2+], these constraints suggest an
important physiological role for MyBP-C in preventing muscle hypercontractility
(Spudich, 2014). Although our studies focused on MyBP-C N-terminal interactions
with actin, they certainly do not preclude MyBP-C interaction with myosin, and may
indeed suggest interactions both myosin and actin, possibly even simultaneously.

CHAPTER SEVEN
UNLOADED SHORTENING IN VITRO:
FROM STEADY-STATE TO DYNAMIC CONTRACTION
7.1 Abstract
How does MyBP-C regulation of steady-state contractile properties translate to
dynamic contraction? To answer this question, unloaded shortening kinetics
experiments were applied to determine how MyBP-C isoforms may differentially
regulate dynamic contraction. Using cultured adult rat ventricular myocytes (ARVM)
as our baseline model, we overexpressed full-length, cMyc-tagged ssMyBP-C,
fsMyBP-C, and cMyBP-C using adenoviral constructs (Figure 25). After 48H in
culture, biochemical and unloaded shortening analysis were used to determine
expression, localization, and function. Western blot demonstrated partial
replacement of the endogenous cMyBP-C in cardiac cells, and immunofluorescence
demonstrated localization of exogenously-expressed MyBP-C isoforms
approximately within the C-zone. Surprisingly, functional data demonstrates no
change in contraction kinetics, but ARVM overexpressing ssMyBP-C and fsMyBP-C
exhibited faster relaxation kinetics relative to cMyBP-C. This suggests that cMyBP-C
expression may prolong relaxation kinetics and/or ssMyBP-C and fsMyBP-C
facilitate faster relaxation kinetics. To parse out the potential mechanisms behind
this unexpected result, computer modeling was employed next.
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Figure 25. Adenoviral-mediated overexpression of MyBP-C in ARVM. Adult
rat ventricular myocytes (ARVM) were isolated, infected with full-length, cMyctagged MyBP-C isoforms, and cultured for 48 hours. Replacement levels,
localization, and unloaded shortening function was then measured.

92
7.2 Results
7.2.1 Replacement Levels
ARVM were infected with adenoviral constructs (MOI: 1000) overexpressing fulllength, Myc-tagged ssMyBP-C, fsMyBP-C, and cMyBP-C, and cultured for 48 hours.
After 48 hours, ARVM were prepared for Western blot analysis to determine the
amount of replacement of endogenous cMyBP-C (Figure 26). ARVM groups,
including an uninfected control (UI), were probed with antibodies for ssMyBP-C,
fsMyBP-C, cMyBP-C, and cMyc antibodies to determine the amount of exogenously
expressed MyBP-C isoforms present in ARVM. Results demonstrate that ARVM
infection was specific to the adenoviral construct, as well as cMyc. Due to limitation
of culture time (48 hours), replacement levels were low, though still significantly
higher compared to UI controls and not significantly different between groups.
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Figure 26. Adenoviral constructs partially replaced endogenous MyBP-C. .
ARVM infected with adenoviral constructs overexpressing full-length, myc-tagged
MyBP-C isoforms were cultured for 48 hours (MOI 1000). Uninfected ARVM were
included as controls. (left) Western blots demonstrate specific expression of
ssMyBP-C and fsMyBP-C. Due to the presence of endogenous cMyBP-C in ARVM,
adenoviral-mediated MyBP-C expression was determined by cMyc tag detection.
All analyses are shown normalized to ß-actin. (right) Adenoviral-mediated
overexpression of ssMyBP-C (red stripes), fsMyBP-C (blue stripes) and cMyBP-C
(black stripes) partially replaced endogenous cMyBP-C (black solid), as
demonstrated by densitometry analysis. There were no significant differences in
replacement levels between adenoviral-mediated ssMyBP-C, fsMyBP-C, and
cMyBP-C.
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7.2.2 Localization determined by IF
Infected ARVM were also imaged using immunofluorescence, and included
immunolabeling with α-actinin, which detected the Z-disc locations (Figure 27).
This allowed visualization of the exogenously expressed MyBP-C within the
sarcomere. IF data demonstrates that exogenously-expressed MyBP-C isoforms
were localized specifically within the sarcomere and probably within the C-zone, as
determined by doublets located within the Z-discs. Resolution of the IF images were
not precise enough to determine whether adenovirally-mediated expression of
MyBP-C caused localization into the adjacent D-zone.
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Figure 27. Exogenous MyBP-C isoforms localized within the sarcomere. ARVM
infected with adenoviral constructs overexpression of full-length, myc-tagged
ssMyBP-C, fsMyBP-C and cMyBP-C were cultured for 48 hours. Localization of
exogenous (A-F) ssMyBP-C, (G-L) fsMyBP-C, and (M-R) cMyBP-C was detected
using immunofluorescence. Staining for α-actinin delineates the location of
cardiomyocyte Z-discs, the borders of the sarcomere (A, D, G, J, M, P). Localization
of adenoviral-mediated overexpression of MyBP-C was detected using antibodies
for ssMyBP-C (B, E) fsMyBP-C (H, K) and cMyc (N, Q). Merged images demonstrated
MyBP-C expression was limited specifically within the sarcomere (C, F, I, L, O, R).
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7.2.3 Unloaded Shortening
After 48 hours in culture, ARVM were paced (2.0 ms, 1 Hz, 20V), and contractile
kinetics were analyzed. Baseline parameters were not significantly different, such as
resting sarcomere length nor percent shortening. Combined traces of each group
demonstrated no significant changes in contraction kinetics, but suggested MyBP-C
isoforms altered relaxation kinetics (Figure 28). Time to %Baseline is a measure of
how fast a cell returns to resting sarcomere length (Baseline). Thus, time to 50%
baseline is how long the cell takes from peak contraction to 50% of its resting
sarcomere length. Quantification of time to 10% baseline, 50% baseline, and 90%
baseline reveals cMyBP-C prolongs relaxation kinetics. Fitting of the relaxation
constant, tau, also demonstrates cMyBP-C extends the amount of time the cell takes
to relax.
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Figure 28. cMyBP-C prolongs relaxation kinetics. (far left) Unloaded shortening
was measured by changes in sarcomere length (SL) during dynamic contraction
and relaxation (ARVM paced at 1Hz, 20V, 2ms). Trace images of combined
unloaded shortening demonstrates changes to relaxation kinetics (error bars
removed for clarity). Relaxation kinetics were quantified by (top left) time to %
baseline, how fast the cell returns to a % of resting SL, and (top right) relaxation
constant tau, a logarithmic fit of the relaxation curve. Both relaxation parameters,
combined with composite traces of unloaded shortening, demonstrate cMyBP-C
prolongs relaxation kinetics. (graphs represented as mean ± SEM, *p<0.05 vs.
uninfected controls, #p<0.05 vs. cMyBP-C). (bottom left) Resting sarcomere length
of ARVM were unchanged suggesting similar starting points of contraction.
(bottom right) Percent shortening was also not different between groups
suggesting similar contractility. (n=42-78 cells, n= 4-6 animals)
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7.3 Discussion
To our surprise, MyBP-C overexpression in ARVM resulted in changes to relaxation
kinetics, while no changes were detected in contraction kinetics. This may have
been due to limitations of the experimental parameters and/or the ARVM model
system. Several scientific and practical considerations were taken when designing
the experiment to accommodate the ARVM model. For example, unlike previous
steady-state experiments that used just the N-terminal region, full-length MyBP-C
isoforms were used, because our studies have previously demonstrated abnormal
localization and function due to the lack of the C-terminal region in the ARVM
system (Kuster et al., 2015), although the N-terminal region may still localize within
the A-band (Herron et al., 2006). Immunofluorescence imaging revealed adenoviralmediated MyBP-C isoforms expressed and localized properly to the sarcomere Aband where myosin thick filaments reside (Figure 27), and doublets reveal the
exogenously-expressed MyBP-C may even have localized specifically within the Czone, though IF images were not at sufficient resolution to preclude possible
expression in the D-zone as well. Similarities between the MyBP-C isoforms in the Cterminal region suggest potential for such proper C-zone localization. However, the
PEVK repeats of cardiac and skeletal isoforms of titin (to which MyBP-C C-terminus
purportedly anchors to the thick filament) have distinctive binding properties
(Linke et al., 2002), and one can not presume skeletal MyBP-C isoforms would bind
to cardiac titin PEVK with the same affinity, and therefore affect contractile kinetics.
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In addition, only partial replacement of the endogenous cMyBP-C occurred
after 48 hours, suggesting the changes in relaxation kinetics were a combination of
the contribution of endogenous cMyBP-C and exogenous MyBP-C isoforms. While
percentage of cells that contract in the adult rat cardiomyocyte system is considered
greater than mouse(Pavlovic, McLatchie, & Shattock, 2010), cellular viability is still
limited post-isolation(Westfall, Rust, & Metzger, 1997) due to its lack of
regenerative and proliferative ability(van Berlo et al., 2014). This allows adenoviralmediated expression from 30% to 90% replacement of smaller proteins, but in
those instances, structural integrity is compromised, as shown in their IF images
(Fink et al., 2001; Westfall et al., 1997). Furthermore, these functional experiments
were in permeabilized cells rather than intact cells, and cell sarcomere lengths were
mechanically set. In my preparations for intact cardiomyocytes, reliable cell viability
could only be maintained for 48 – 72 hours. After this time period, detectable
sarcomere lengths were considerably shorter. In addition, cardiomyocyte structure
had either noticeably deteriorated, maintained their structure but were no longer
responsive to electrical stimulation, or responded to stimulation initially followed
by rapid deterioration in cell structure.
Isolation and culture techniques appear to be as varied as the labs that
implement primary cardiomyocyte systems (Wolska & Solaro, 1996). Therefore,
longer culture times were attempted via changing several parameters that have
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been suggested to work, including, but not limited to, changing media more
frequently (every 12 hours) and adding ascorbic acid to remove oxygen radicals and
cellular waste, cellular pacing (0.1 Hz, 2.0ms) during culture to maintain
contractility, and addition of 2,3-butanedioxome (BDM) to inhibit contraction
during culture. The most successful protocol tested was an adaptation of a longterm mouse cardiomyocyte isolation protocol (O'Connell, Rodrigo, & Simpson,
2007) that utilized a custom HMEM-based media that contained BDM, which was
then carefully and slowly washed out with Tyrode’s solution just prior to
experimentation. This was a compromise of several systems we tested, and is not
without its own advantages and disadvantages, as discussed previously. However,
this method yielded the most consistently usable cells and was therefore
implemented for the in vitro unloaded shortening.
Regarding the fact that only relaxation kinetics were altered and not
contraction kinetics, the limitations in experimental parameters (1 Hz, 2.0 ms) could
have limited what changes could be detected. Voltage was most commonly set at
20V, but was adjusted such that the minimal amount was required to stimulate the
ARVMs. At a frequency of 1 Hz, the contraction rate of ARVMs would closer reflect
that of a human heart. However, these conditions do not truly reflect that of a
human heart nor rodent heart, because the cardiac system would not have the same
MHC composition as humans (Miyata, Minobe, Bristow, & Leinwand, 2000), and is
paced much slower than the frequency experienced in a rat heart (Azar, Sharp, &
Lawson, 2011). Furthermore, the MyBP-C isoforms used in all steady-state and
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dynamic experiments were that of mouse isoforms, though mouse and rat MyBP-C
isoforms share similar homology. While there is much to be said regarding the
caveats of choosing particular conditions, the mix-and-match of different systems in
the literature have yielded many answers as well as more questions.
The question originally proposed was: how does MyBP-C regulation of
steady-state contractile properties translate to dynamic contraction? The answer
from unloaded shortening in intact myocytes turned out to be: cMyBP-C prolongs
relaxation kinetics relative to ssMyBP-C and fsMyBP-C. The question now becomes:
by what mechanism does cMyBP-C facilitate prolonged relaxation kinetics relative
to ssMyBP-C and fsMyBP-C?

CHAPTER EIGHT
UNLOADED SHORTENING IN SILICO:
COMPUTER MODELING DEMONSTRATES THIN FILAMENT ACTIVATION BY MYBPC ISOFORMS CONTRIBUTES TO REGULATION OF RELAXATION
8.1 Abstract
To determine whether our steady-state observations on thin filament activation can
explain changes in relaxation kinetics during dynamic contraction, we utilized an
online muscle simulator (OMS) that had been previously established to simulate
unloaded shortening of a single cardiomyocyte (Campbell et al., 2013; Kuo et al.,
2014). I applied parameters based on our steady-state experiments to the OMS that
accounted for differential capacity to activate the thin filament (Figure 29 and
Table 5). The steady-state studies suggest that ssMyBP-C activates the thin filament
at low [Ca2+], fsMyBP-C at high [Ca2+], and cMyBP-C activates at both low and high
Ca2+. When accommodating for the greater capacity of cMyBP-C to activate the thin
filament, in silico unloaded shortening traces demonstrate increased thin filament
activation capacity results in prolonged relaxation kinetics (Figure 29). The rightshift of cMyBP-C’s relaxation trace in silico reflects the in vitro unloaded shortening
data, in which cMyBP-C prolongs relaxation kinetics relative to ssMyBP-C and
fsMyBP-C (Figure 28, 29). Combined, these studies indicate that thin filament
activation capacity can directly contribute to relaxation kinetics.
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8.2 Results
8.2.1 Thin filament activation
In collaboration with Dr. Stuart Campbell, we investigated the effects of
ssMyBP-C, fsMyBP-C, and cMyBP-C using a muscle simulation program. While
alterations to the simulations were conducted by myself and conclusions made in
this section are my own, the muscle simulation program itself was written and made
available for use by Dr. Campbell. The results from the simulations reproduced are
here with permission.
The muscle simulation (OMS) applied in the present study was previously
used to model unloaded shortening of intact cardiomyocytes(Campbell et al., 2013;
Kuo et al., 2014; Sheikh et al., 2012), and adapted for the purpose of modeling how
different MyBP-C isoforms may alter contractile kinetics. Previous implementations
of this simulation did not account for contribution of cMyBP-C, and thus provided an
opportunity to model how all three isoforms regulate contractile function. Based on
the results from steady-state experiments, I concluded that MyBP-C isoforms
differentially regulated thin filament activation: ssMyBP-C activates the thin
filament at low [Ca2+], fsMyBP-C activates at high [Ca2+], and cMyBP-C activates at
both low and high [Ca2+] (Online Video 3 https://vimeo.com/148663467).The
online muscle simulation has several parameters relating to various contractile
properties, and the closest parameter that fit changes in thin filament activation is
kon, or the rate constant for Ca2+ association(Kreutziger, Gillis, Davis, Tikunova, &
Regnier, 2007) (Table 5). Due to the complexities of the simulation, only one
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parameter was altered to minimize variability in the output. Simulation results
demonstrate that increased ability for thin filament activation, the relaxation
kinetics of the unloaded shortening trace is clearly prolonged with no such changes
in contraction kinetics. This data suggests that the expanded capacity of thin
filament activation by cMyBP-C accounts for the prolonged relaxation kinetics
demonstrated by in vitro unloaded shortening experiments (Figure 29).
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Figure 29. Computer modeling of unloaded shortening demonstrate thin
filament activation can affect relaxation kinetics. To determine whether
steady-state regulations (Figure 12,17,23) can explain observed dynamic
contraction, computer simulations of unloaded shortening were run
accommodating the differential capacity of MyBP-C isoforms to activate the
thin filament. See Table 5 for source values. (bottom) Traces of in silico
unloaded shortening suggest the increased capacity of cMyBP-C to activate thin
filament contributes mechanistically to relaxation kinetics.
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MyBP-C
isoform

kb

ku

kon

koff

fapp

gapp

hf

hb

gxb

gammaB

Temp.
(K)

ssMyBP-C

0.09

0.45

375

0.33

0.30

70e-3

2000e-3

400e-3

0.25

300

323

fsMyBP-C

0.09

0.45

360

0.33

0.30

70e-3

2000e-3

400e-3

0.25

300

323

cMyBP-C

0.09

0.45

500

0.33

0.30

70e-3

2000e-3

400e-3

0.25

300

323

Table 5. Computational modeling parameters account for differential thin
filament activation (kon) capacities of MyBP-C. (kb: rate of Ca2+ binding to troponin
C; ku: rate of Ca2+ dissociation from troponin C; kon rate of tropomyosin transition
from blocked to closed state; koff: rate of tropomyosin transition from closed to
blocked; fapp: rate of XB attachment; gapp: rate of XB detachment from prepowerstroke state; hf: rate of forward powerstroke; hb: rate of reverse
powerstroke; gxb: rate of XB detatchment from the post-powerstroke state;
gammaB: cooperative coefficient representing tropomyosin-tropomyosin
interactions; Temp: temperature in degrees Kelvin).
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8.3 Discussion
Our data suggests thin filament activation can directly contribute to
relaxation kinetics. I theorize this effect occurs because MyBP-C activation of the
thin filament would favor cross-bridge attachment. Because cMyBP-C has a greater
capacity to activate the thin filament, the actin-myosin interaction would
presumably be stronger and longer. The longer duration of these cross-bridges
would prolong relaxation, which is observed in both in silico and in vitro unloaded
shortening. This effect is summarized in Online Video 4, and has been suggested
previously(Davis et al., 2016; Moss, 2016). However, important limitations should
be addressed to maintain perspective when interpreting these results. It is worth
noting that our modeling only accounted for differential MyBP-C thin filament
activation to focus on how steady-state experiments from the present study
translates to dynamic contraction and by what mechanism.
The simulation does not account for the presence of endogenous cMyBP-C
present in the ARVM system, and assumes the only contribution to relaxation
kinetics is that of the particular MyBP-C isoform. This is distinctly different from in
vitro experiments, as endogenous cMyBP-C is present in ARVM. One alternative was
to utilize cMyBP-C knock-out mice models that lack cMyBP-C incorporation in the
sarcomere, two of which are available (Harris et al., 2002; McConnell et al., 1999).
As the first experiment conducted to determine differences between the MyBP-C
isoforms, this was not the route chosen due to complications from the development
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of HCM and DCM in these mice that may mask or obscure isoform-specific changes.
In addition, mouse cardiomyocytes are much less resilient than rat cardiomyocytes;
thus, the adenoviral-mediated strategy of gene transfer would be significantly more
difficult to implement or an alternative in vivo delivery approach would have been
required. Therefore, as previously mentioned, the in vitro ARVM express
endogenous cMyBP-C that was only partially replaced by exogenous ssMyBP-C,
fsMyBP-C, and cMyBP-C after 48H in culture. The differences in MyBP-C regulation
of relaxation kinetics is thus likely underestimated by experimental data.
The steady-state experiments that were used to draw conclusions regarding
thin filament activation are also worth considering. Steady-state experiments are
like snapshots of a dynamic process, and the variety of experiments used capture
the process from different vantage points. Both of which lend insight into MyBP-C
regulatory function, but highlight considerations when translating the results.
Besides the fact that the changes to the simulations were made based on steadystate and not dynamic experimental data and that several steady-state experiments
were utilized, the most discernable difference is the use of N-terminal versus fulllength MyBP-C isoforms in the steady-state and full-length. As MyBP-C localization
is highly regulated within the C-zone, the effects using N-terminal proteins is likely
representative of an enhanced effect of MyBP-C. This indicates that our steady-state
experiments exaggerate MyBP-C isoform function while dynamic experiments
underestimates MyBP-C function. Thus, the relaxation data, however congruent,
must be interpreted cautiously.
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In both the in silico and in vitro unloaded shortening studies, the stimulation
parameters of cardiomyocytes were not altered, which allowed for comparison, but
also limited the scope of what we could ascertain between MyBP-C isoforms. The
simulator did not yet have function to alter the stimulation parameters, which
would then therefore allow for greater flexibility in potential comparisons with in
vitro data. Changes in frequency, pulse duration, and voltage could be altered to
more clearly parse out differences between MyBP-C isoforms, such as kineticsfrequency relationships. Permeabilized ARVM experiments can also be pursued to
determine force-frequency and force-pCa relationships, bridging the gap in
understanding from the steady-state fiber function data and the dynamic intact
myocytes data. These experiments would provide greater evidence that thin
filament activation can contribute to changes in relaxation kinetics, and also
determine whether this mechanism precludes alternative roles for MyBP-C in
regulating contraction.
Do relaxation results have any physiological implications?
Why does MyBP-C regulate relaxation? The answer may lie in what we know
regarding the expression profile of skeletal MyBP-C. In a healthy, adult heart,
fsMyBP-C is not expressed, but is present after some insult to the heart, such as HF
(B. Lin et al., 2013). HF is defined by the American Heart Association as: ‘… a
complex clinical syndrome that results from any structural or functional impairment
of ventricular filling or ejection of blood.’ (Yancy et al., 2013)
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Because mutations in the cMyBP-C are a primary cause of HCM, the
ventricular or septal wall thickens, and the ventricular chamber has difficulty filling
with blood. In order to compensate for the lack of ability to relax, fetal isoforms of
MyBP-C that facilitate relaxation kinetics are expressed. This reversion to fetal gene
programming has been suggested to be cardioprotective(Depre et al., 1998; Rajabi
et al., 2007). Conversely, disruption of the normal signaling pathways that regulate
gene expression have been suggested to be maladaptive (Dirkx, da Costa Martins, et
al., 2013; Hannenhalli et al., 2006). The expression of fsMyBP-C in the heart during
HF is therefore an artifact of these changes. The truth is likely somewhere in the
middle: the expression of fetal gene programming may express contractile proteins
that are initially compensatory, but long-term re-expression of these non-native
isoforms eventually becomes disadvantageous and harmful.
The skeletal isoforms are expressed in the heart only conditionally and in
relatively low quantities, and thus the physiological impact of unloaded shortening
results may be limited in scope. The question then is: do changes in relaxation
kinetics reflect a physiological phenomenon in the context of skeletal muscles? The
key to answering this question may rest within what we know about skeletal
disease-causing mutations in ssMyBP-C and fsMyBP-C. Currently, mutations in the
skeletal MyBP-C isoforms are known to cause three distinct skeletal myopathies: 1)
distal arthrogryposis, Type 1 (DA1) 2) distal arthrogryposis, Type 2 (DA2) and 3)
lethal congenital contracture syndrome, type 4 (LCCS4). In these diseases, patients
experience the inability or extreme contractures of the hand and feet, a congenital
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deformity known as ‘club foot’ or ‘club hand’. Patients with DA2 also exhibit
distinct contractures of craniofacial muscles. These abnormalities suggest skeletal
MyBP-C is responsible for relaxation of these muscles and important in the
structural development of these skeletal muscles. However, there is a noticeable
lack of skeletal muscle deformities in other muscles in these human patients, such as
large locomotor muscles in the leg and vital diaphragm muscles required for
breathing. This may indicate that MyBP-C expression is more critical for muscles
that require fine motor skills, or these known mutations only affect the molecular
function of MyBP-C that are essential in the hands and feet.
8.5 Alternative molecular mechanisms
As previously suggested, MyBP-C may also act as a viscous load (Palmer et al.,
2011; A. Weith et al., 2012; A. E. Weith et al., 2012) to put a brake on contraction
during the later stages of contraction (Previs et al., 2012). MyBP-C N-termini
binding to actin may act as a drag on actin (Walcott et al., 2015) or form a so-called
“C-bridge,” in which MyBP-C binding to actin creates a second thick-thin filament
interaction, though the latter mechanism may be more pronounced had full-length
MyBP-C been used. Whether MyBP-C enhances cross-bridge duration, viscous load,
or actin drag, unloaded shortening data suggests relaxation kinetics can be
influenced as a result. Further complicating matters, other assays have suggested
changes in functional effects by MyBP-C can be explained by a tethering mechanism
in which MyBP-C acts as a load on myosin, limiting cross-bridge formation
(Barefield & Sadayappan, 2010). In support of this mechanism, high Ca2+ causes a

112
conformational change in cMyBP-C N-terminal region that may favor myosin
interaction (Previs et al., 2016). Regardless of mechanism, these constraints on the
sarcomere at higher Ca2+ suggest a role for MyBP-C in limiting muscle
hypercontractility: which is often observed in HCM, of which cMyBP-C mutations
are a major cause (Spudich, 2014). As such, our experiments do not preclude MyBPC interaction with myosin, or other regulatory effects on the thin filament (Walcott
et al., 2015). Indeed, though our mechanistic studies features MyBP-C interactions
with actin, our data also suggests further studies are required into different MyBP-C
isoforms’ interactions with myosin to fully understand the function of each MyBP-C
isoform. More specifically, focus needs to be directed towards the function of
skeletal isoforms of MyBP-C where they are predominantly expressed: in skeletal
muscles.

CHAPTER NINE
FSKO MICE: FAST-SKELETAL MYBP-C KNOCK-OUT
SKELETAL MUSCLE DEFICIENCES OFFSET ONE ANOTHER
9.1 Abstract
FSKO (fast-skeletal MyBP-C knock-out) mice are the first mouse model designed to
investigate the function of fsMyBP-C. EDL (extensor digitorum longus) muscle fibers
from non-transgenic (NTG), heterozygous (FSKO-HET), and homozygous (FSKOHOM) were selected for analysis by force-ATPase assay. EDL were selected due to
robust expression of fsMyBP-C in NTG muscles and would therefore exhibit the
greatest alterations to molecular function. Our results demonstrate that FSKO mice
do not alter force generation nor Ca2+-sensitivity of force development. Stiffness is
decreased in FSKO-HOM mice, suggesting that the absence of fsMyBP-C releases a
load on myosin that would facilitate myosin binding to actin and is therefore
predicted to promote force production. In support of this, the ATPase activity in
FSKO-HOM mice is also decreased, suggesting less energy expenditure is required to
form an attached cross-bridge. However, rate of tension redevelopment (ktr) is
significantly reduced in FSKO-HOM mice, which is predicted to decrease force
production. Together, this suggests that absence of fsMyBP-C results in offsetting
deficiencies in the FSKO mice, though the contribution of ssMyBP-C needs to be
considered.
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9.2 Results
9.2.1 Expression profile in FSKO mice
Western blot analysis was used to determine the protein expression profile of NTG,
HET, and HOM FSKO mice that were 5 – 6 months old. FSKO mice were generated by
targeting exons 2-4, and 20-22 of the MYBPC2 gene. The expression of fsMyBP-C and
ssMyBP-C of NTG FSKO mice (Figure 31), which is C57BL6 background, matches
that of FVB/N WT mice (Figure 7). Four commonly-studied muscles were selected
to represent different types of skeletal muscles: extensor digitorum longus (EDL),
flexor digitorum brevis (FDB), a slow-type muscle, soleus (SOL), and tibialis anterior
(TA). The EDL and FDB are considered fast-type skeletal muscles, SOL is a slowtype, and TA is a mix of fast- and slow-type muscle fibers. The EDL and TA are on
analogous to muscles on your shin, the FDB is located on the soles of your feet, and
the SOL is located beneath your calf muscles. In NTG and HET mice, ssMyBP-C is
present in all skeletal muscles tested and fsMyBP-C is expressed only in EDL and TA.
However, HOM mice demonstrated a complete lack of fsMyBP-C in all muscles, and
ssMyBP-C expression levels are unchanged in response to the lack of fsMyBP-C in
these studies (Figure 32).

Date of Birth (F1)

04-26-2014.

Description

Total: 10 pups; LUC002_1B9 1 to 10.

PCR-Positive Pups

♂

3

LUC002_1B9：1, 5, 9.

♀

1

LUC002_1B9：3.
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F1 Genotyping Strategy:
Wildtype allele
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Figure 30. Targeting strategy for FSKO mice. (top) wild-type fsMyBP-C gene
(bottom) targeted fsMyBP-C gene. Exons 2-22 were replaced with a neomycin
resistance gene.
1/7
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Figure 31. FSKO mice lack fsMyBP-C. Dual-color western blot was employed to
determine expression profile of FSKO (fast-skeletal MyBP-C knock-out) mice,
which are of C57BL6 background. NTG and HET FSKO mice expression profile
reflects that of FVB/N WT mice (Figure 7)
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Figure 32. FSKO mice do not significantly alter ssMyBP-C expression. (left)
Knock-out of fsMyBP-C does not alter the expression of ssMyBP-C, as determined
by quantification of Western blots. (right) fsMyBP-C is not present in FSKO-HOM
mice, though there may be partial dysregulation in HET mice.
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9.2.2 Force Generation and Ca2+-sensitivity of force-development
For comparison with previous steady-state experiments, the force-ATPase assay
used was essentially the same with some distinct changes to accommodate the
skeletal muscle. EDL muscle fibers were prepared as previously described (Wood,
1978; Wood, Zollman, Reuben, & Brandt, 1975). Briefly, muscles were excised
tendon-to-tendon and tied to wooden sticks with silk surgical suture such that the
muscle was taut to prevent damage during the permeabilization/cryopreservation
process. The muscle were skinned over a period of at least 2 weeks in 1:1
glycerol/relax solution at -20°C, after which the fibers were mechanically separated,
t-clipped and attached to a force transducer and length controller. The sarcomere
length of EDL fibers were set to a slack length of 2.5 µm (Hofmann, Greaser, & Moss,
1991)
Force-pCa relationships demonstrate no significant differences between
NTG, HET, and HOM FSKO mice (Figure 33). While the result was expected between
NTG and HET mice, the lack of change in FSKO-HOM mice was surprising. Once the
force was normalized, there was no observable shift in force-pCa curves between all
groups, and quantification of the pCa50 confirmed there were no changes in Ca2+sensitivity of force development (data not shown).
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Figure 33. FSKO mice do not exhibit changes in force nor Ca2+-sensitivity.
Knock-out of fsMyBP-C did not significantly alter force-pCa relationship (left), nor
relative force-pCa relationship (right). Graphs represented as mean ± SEM, *p<0.05
vs. NTG, n=5-6 animals.
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9.2.3 Stiffness-Force Relationship and ATPase-Force
Myosin S1 interaction with actin is a key event in the contraction process, and
MyBP-C regulation of this process is likely due to either interaction with actin
and/or myosin. Therefore, I analyzed parameters that would elucidate how fsMyBPC regulates myosin and actin by analyzing stiffness and ktr, respectively. It should be
noted that these measurements are influenced by several factors. Stiffness is a
measure of attached cross-bridges and is proportional to tension. Stiffness is
measured by applying rapid, oscillating length changes and recording the change in
force (Δforce/Δlength) (Ford, Huxley, & Simmons, 1977). Results demonstrate no
changes in maximal stiffness levels (Figure 34), but when stiffness was normalized
to force, FSKO-HOM mice demonstrated significant decrease stiffness-force
relationship. This suggests fsMyBP-C may place a load on myosin, and this load is
released due to the absence of fsMyBP-C in FSKO-HOM mice.
The lack of inhibitory activity of fsMyBP-C in FSKO-HOM mice would predict
increased force generation, but this was not the case (Figure 33). However, the
ATPase-force relationship of FSKO-HOM mice suggest that less energy expenditure
is required per unit of force (Figure 35). Quantification of ATPase-force slopes
determined tension cost, but only demonstrates a trend towards decreased energy
expenditure and is not significantly different.
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Figure 34. FSKO mice exhibit reduced stiffness. (left) knock-out of fsMyBP-C did
not alter maximal stiffness levels. (right) However, reduced stiffness per unit force
demonstrates fewer cross-bridges are required to generate force. Graphs
represented as mean ± SEM, *p<0.05 vs. NTG, n=5-6 animals.
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Figure 35. FSKO mice trend towards reduced ATPase activity. (left) ATPaseforce relationship demonstrates the energy expenditure required to generate
force. (right) Quantification of slopes of the ATPase-force relationship gives
tension cost, which trends towards significance, but is not significantly different.
Graphs represented as mean ± SEM, *p<0.05 vs. NTG, n=5-6 animals.
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9.2.4 Rate of Tension Redevelopment
The rate of tension redevelopment (ktr) is a measure of thin filament activation, as
previously described in Chapter Five. After the previous experiments were
completed, ktr was analyzed following a rapid release-restretch maneuver. Results
demonstrate that, at high Ca2+ (pCa 4.5), FSKO-HOM mice have significantly
decreased ktr relative to NTG, but not FSKO-HET (Figure 36). However, at low Ca2+
(pCa 6), ktr is not significantly different between all groups. First, this suggests
fsMyBP-C also regulates thin filament activation in skeletal muscles. Second,
regulation of fsMyBP-C regulation of thin filament activation seems to limited to
higher [Ca2+]. The lack of fsMyBP-C in FSKO-HOM mice thus would partially
diminish thin filament activation in the sarcomere, and therefore, one would predict
reduced force production and this is not the case (Figure 33). Recall that stiffness
data suggest FSKO mice exhibit reduced myosin inhibition, and therefore the
opposing effects may cancel one another out.
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Figure 36. FSKO mice are deficient in thin filament activation at high Ca2+.
(left) FSKO mice exhibit reduced ability to activate the thin filament, as
demonstrated by reduced ktr. (right) At submaximal Ca2+, there was no difference,
suggesting fsMyBP-C regulates thin filament activation specifically at higher Ca2+
levels in striated muscle. Graphs represented as mean ± SEM, *p<0.05 vs. NTG, n=46 animals.
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9.3 Discussion
Collectively, the current data on FSKO mice demonstrate two intriguing effects due
to the lack of fsMyBP-C. First, FSKO-HOM mice exhibit decreased stiffness-force
ratios, suggesting that fsMyBP-C normally places a load on myosin. One would
predict the release of this inhibitory load would result in increased force, but the
data showed no change in force production (Figure 33). Second, FSKO-HOM mice
have decreased ktr, suggesting fsMyBP-C also activates the thin filament. Therefore,
the diminished activation capacity would thereby also result in reduced force
production, but again force was unchanged. At face value, these data sets do not
make any sense on their own. Together, these data suggest that fsMyBP-C has dual
effects on myosin and actin that offset one another and is therefore why no change
in force nor Ca2+-sensitivity of force development was observed. Moreover, these
effects may be Ca2+-dependent and occur at different stages of contraction. For
example, inhibition of myosin by fsMyBP-C may occur during relaxation, while
activation of actin thin filament may occur during contraction. The ktr data certainly
suggest that fsMyBP-C activation capacity occurs at higher [Ca2+] and is congruent
with previous data in the cardiac muscle system that suggested fsMyBP-C operates
at higher, but not lower [Ca2+] (Figures 17). However, this range is shifted towards
maximal [Ca2+].
One noticeable observation from the ATPase-force relationship is that FSKOHOM mice trends towards a decrease in ATPase activity, but the quantification of
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the ATPase-force slopes to determine tension cost is not significantly different. This
brings up an important stipulation regarding the muscle fibers used. Closer
inspection revealed the possibility of distinct subpopulations within the data set. In
other words, the fibers in the EDL fiber bundles may have consisted of distinct types
of fibers (Augusto, 2004). When manually dissecting the fibers under the scope, one
can not accurately distinguish the difference between fiber types, and thus the EDL
fiber bundles used were of unknown composition. In combination with the presence
of ssMyBP-C, the unknown percentage of fast- vs. slow-type fibers may contribute to
the relatively muted effects observed in the functional assays. Therefore, to fully
elucidate fsMyBP-C function, other studies must be disseminated to piece together a
comprehensive functional story.
Intriguingly, there is one recent study that also focused on fsMyBP-C, though
in a zebrafish model (M. Li et al., 2016). In this study, morpholino antisense
nucleotides were used to knockdown approximately 50% of fsMyBP-C, variant 2B.
Despite vastly different methodologies, this study is worth discussing, because it is
currently the only study that focuses on fsMyBP-C. Their results demonstrated
structural abnormalities, such as shorter sarcomere lengths, a well as functional
changes, such as increased maximal shortening velocity and decreased active force.
The latter functional effect reflects our own data suggesting fsMyBP-C places a load
on myosin. The removal of this load would thereby also promote shortening velocity
in both FSKO mice and the zebrafish morphants. However, limitations must be
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considered when comparing these very different studies. One significant difference
between the FSKO mice and zebrafish was how drastic the difference in deficiencies
observed. In the zebrafish study, just 50% knockdown of fsMyBP-C, variant 2B
resulted in gross morphological shrinkage, contractile changes in shortening
velocity, as well as elevated apoptosis and protein-degradation factors. In the FSKO
mice I studied, there is absolutely no fsMyBP-C present, though the functional
changes were mild by comparison. The difference in species may explain this
dichotomy. First, fsMyBP-C variant 2B is the dominant isoform in zebrafish, with
some fsMyBP-C variant 2A, and very little ssMyBP-C. Conversely, in mice, ssMyBP-C
is by far the predominant MyBP-C isoform, being expressed in all skeletal muscles
and fsMyBP-C is only expressed in mixed-type muscles. Therefore, we would expect
a stronger phenotype in a ssMyBP-C knock-out mouse model rather than the current
fsMyBP-C knock-out mice. Second, there are several known splice variants of
ssMyBP-C in mammals and only one fsMyBP-C isoform (Ackermann, Kerr, et al.,
2015; Ackermann & Kontrogianni-Konstantopoulos, 2011b, 2013). In contrast, the
opposite is true in zebrafish: there are two fsMyBP-C variants and only one ssMyBPC variant. Third, cMyBP-C is present in zebrafish skeletal muscle during
development(Chen et al., 2013; Cheng et al., 2013), but cMyBP-C is not present at all
in mouse skeletal muscle during at any time (Gautel et al., 1998; B. Lin et al., 2013).
The last limitation that I will discuss is that while their structural assays
demonstrate that sarcomere length is diminished after fsMyBP-C knockdown (M. Li
et al., 2016), their active force measurements to not normalize to the lower
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sarcomere length. Therefore, the higher force production observed in controls may
simply be due to changes in length (de Tombe et al., 2010).
These limitations are not meant to diminish the results from the zebrafish
study. On the contrary, these simply illustrate the need for more in depth
investigation into the function of fsMyBP-C. Clearly, deficiency in MyBP-C can
directly affect structure and function. This becomes particularly vital as mutations
in the skeletal MyBP-C isoforms are discovered as the cause for skeletal myopathies.
(Bayram et al., 2016; Gurnett et al., 2010; X. Li et al., 2015).

CHAPTER TEN
FUTURE DIRECTIONS
Abstract
There are many avenues of research to pursue in the relative short-term to
elucidate more about the MyBP-C family of proteins. Even within the research
specific to cMyBP-C, much has yet to be determined. It is very exciting to think about
the numerous and intriguing avenues of research that can be conducted in the near
future.
Recombinant Proteins with phosphomimetic sites and PKA challenge
It is well known that cMyBP-C has several phosphorylation sites that alter its
regulation of actin and myosin (Barefield & Sadayappan, 2010; Sadayappan & de
Tombe, 2012), and studies are always being conducted on the mechanism of cMyBPC phosphorylation (Colson et al., 2016; Previs et al., 2016). However, there is little
known about how skeletal MyBP-C isoforms are phosphorylated. ssMyBP-C has
several known phosphorylation sites (Ackermann & Kontrogianni-Konstantopoulos,
2011a), and circumstantial evidence suggests fsMyBP-C also has phosphorylation
sites(Ackermann, Ward, et al., 2015), which will have to be clearly identified using
mass spectrometry. Isoproterenol challenge to intact cells or incubation of PKA in
permeabilized fiber studies would be able initially highlight how skeletal MyBP-C
phosphorylation modulates their regulation. To more clearly delineate how skeletal
129
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MyBP-C phosphorylation sites alter regulation of function, phosphomimetic and
phosphoablated recombinant proteins can be utilized to determine how they affect
interactions with actin and myosin, as well as function in a variety of single myocyte
and fiber bundle assays. Future studies could also incorporate partial
phosphomimetic/phosphoablated sites to determine hierarchy of regulation of
these sites. Finally, transgenic models expressing phosphomimetic or
phosphoablated MyBP-C may be necessary to demonstrate a physiological
consequence of skeletal MyBP-C PTM.
Sufficiency of N-terminal domains (e.g. C0-P/A-C1-C2)
Studies have painstakingly demonstrated which domains of cMyBP-C are
required for regulation of function (Bezold, Shaffer, Khosa, Hoye, & Harris, 2013;
Colson et al., 2012; Herron et al., 2006; Kensler, Shaffer, & Harris, 2011; Razumova
et al., 2008). Presumably, skeletal MyBP-C functional domains are similar, but there
are distinct structural differences between MyBP-C isoforms. Determination of
analogous or distinct binding and functional regulation may yield greater insights
into MyBP-C function. Just within the context of the FSKO mice, determining
whether the addition of recombinant fsC1C2 is sufficient to recover changes in
function would be an important first step and relatively simple experiment, given
the materials and baseline data are already there. Incubation with various lengths of
MyBP-C N-termini in skeletal fibers or adenoviral-mediated expression in skeletal
muscles may further yield interesting functional regulation, though the latter
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strategy is difficult given the resistance of adult skeletal muscle fibers to
adenoviral infection due to downregulation of adenoviral receptors.
What does the C0 domain do?
One of the most stark differences between cMyBP-C and its skeletal
counterparts is the presence of an additional C0 domain on cMyBP-C: an N-terminal
sequence of approximately 100 amino acids (Harris, Belknap, Van Sciver, White, &
Galkin, 2016; Ratti et al., 2011). The function of this distinct structure in cMyBP-C is
still debated in the literature(Herron et al., 2006). One possible experiment is to
create a recombinant skeletal MyBP-C protein with the C0 domain artificially added
to the N-terminus to investigate whether this would render skeletal MyBP-C binding
and function more similar to that of cMyBP-C. In the same vane, the C0 domain can
be specifically removed and used to demonstrate whether this would render
cMyBP-C more similar in binding and function to that of skeletal MyBP-C. Removal
of the C0 domain has previously been investigated, but not specifically conducted to
differentiate functional regulation between skeletal and cardiac MyBP-C.
MyBP-C, the Myosin Mesa, and the Super-Relaxed State
Recently, research has demonstrated specific interactions of myosin head
and MyBP-C(Spudich, 2015), whose formation entails unknown consequences. The
proposed interaction site between a flat region of the myosin S1 region and the Mmotif of cMyBP-C suggests charged residues are responsible for regulating their
interaction. This interaction may very well be one mechanism that stabilizes the
myosin head in the relaxed state (Woodhead et al., 2005), as well as the super-

132
relaxed state(McNamara et al., 2016). The physiological implication of this
are completely unknown.
MyBP-C, Actin, and the ‘C-bridge’
Myosin S1 interaction with actin forms a cross-bridge that is central to the
sliding filament theory of sarcomeric contraction(Spudich, 2001). However, MyBP-C
activation of the thin filament via binding to actin (Mun et al., 2014) (Figure 23)
would indicate the presence of a second thick-to-thin filament interaction, which is
colloquially known as the ‘C-bridge.’ The C-bridge would presumably not contribute
to active force production directly, but its formation could affect passive tension and
stiffness. Therefore, to elucidate the potential presence or impact of such a C-bridge,
one could simply study function in the presence of a myosin inhibitor, such as BDM
or blebbistatin.
ssMyBP-C splice variants
One factor of complication regarding ssMyBP-C are the numerous splice
variants known, which result ssMyBP-C that have unique N-terminal regions and Cterminal regions (Ackermann, Kerr, et al., 2015; Ackermann & KontrogianniKonstantopoulos, 2011b). While in mouse, only two variants have been identified,
the possibility of specific roles and differential expression of ssMyBP-C variants may
drastically alter known function of ssMyBP-C. Whether ssMyBP-C variations result
in subtle changes in regulation or have completely different regulation is unknown,
and may further elucidate why we express multiple isoforms of MyBP-C.
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in vivo function
The biophysical assays of FSKO mice in the present study sheds light on the
mechanics at the fiber level. However, experiments are necessary to determine
whether fsMyBP-C is necessary in vivo, such as treadmill function, grip strength,
voluntary wheel run, gait/locomotion analysis. More specific analysis can be done
on anesthetized FSKO mice by analyzing torque injury, fatigability, and nerveevoked muscle function. There are two possible scenarios that I predict, both of
which are opposite one another: first, given the mild changes in fiber studies, the in
vivo studies may demonstrate only subtle changes in function. This would require
challenging the animal with stressors, such as forced exercise. Second, the opposite
may occur, where in vivo function is severely diminished. The expression profile of
fsMyBP-C demonstrates its presence in mixed skeletal muscles, such as the EDL and
TA (Figure 7,30), as well as gastrocnemius and quadriceps (data not shown). These
latter muscles suggest fsMyBP-C regulates function of very large muscle groups and
therefore, FSKO mice would exhibit significant in vivo functional deficits.
SSKO mice
Concurrently with the development of the FSKO mice, SSKO mice (slowskeletal MyBP-C knock-out) are now available for study. SSKO mice are not to be
confused with liver-specific squalene synthase knock-out mice, L-SSKO (Nagashima
et al., 2015). In contrast, the SSKO mice exhibit higher rates of early death relative to
the FSKO mice (data not shown), suggesting a greater necessity for ssMyBP-C which
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is expressed in all muscle types. The unique advantage of using SSKO mice is
that the targeting strategy removes all variants of ssMyBP-C, both known and
unknown. Therefore, the functional data from this mouse model would define the
collective function of ssMyBP-C.
DSKO mice as the baseline
Crossing SSKO mice with FSKO mice yields the DSKO mice (double-skeletal
MyBP-C knock-out), which would lack both skeletal MyBP-C isoforms. This is the
baseline that should be used to compare both SSKO and FSKO mice. In FSKO mice,
ssMyBP-C present and therefore, FSKO mice actually demonstrates the contribution
of ssMyBP-C to function. Conversely, SSKO mice still express fsMyBP-C, and
therefore SSKO mice would actually demonstrate the contribution of fsMyBP-C to
function. Thus, comparison to a DSKO mouse model will provide a much clearer
understanding of skeletal MyBP-C.
Length-Dependent Activation
The mechanism behind length-dependent activation (LDA) is still
erroneously taught in medical texts as due to optimal overlap of thick- and thinfilaments(Berne, Koeppen, & Stanton, 2010). However, studies have demonstrated
the precise mechanism may lie within cellular and myofilament properties (Allen &
Kentish, 1985; Kentish, ter Keurs, Ricciardi, Bucx, & Noble, 1986; Kobayashi, Jin, &
de Tombe, 2008; Konhilas, Irving, & de Tombe, 2002a; Kumar et al., 2015; ter Keurs,
Rijnsburger, van Heuningen, & Nagelsmit, 1980), rather than purely structural
explanations (Farman, Walker, de Tombe, & Irving, 2006). More recently, cMyBP-C
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has been demonstrated to specifically regulate length-dependency (Kumar et
al., 2015; Mamidi, Gresham, & Stelzer, 2014; Mamidi et al., 2016; Witayavanitkul et
al., 2014). It should be noted that LDA effects are relatively muted in skeletal muscle
systems (Konhilas, Irving, & de Tombe, 2002b; Konhilas et al., 2003). In these
studies, the partial replacement with the ssTnI significantly blunted LDA, suggesting
isoform-specific and muscle-specific regulation of contraction. However, other
studies have demonstrated that fast-skeletal muscles and cardiac muscles exhibit
more length-dependent effects than slow-skeletal(Konhilas et al., 2002b). This
correlates with the present data that demonstrates fsC1C2 and C0C2 have similar
function at higher [Ca2+]. Therefore, I hypothesize fsMyBP-C has a greater
contribution to LDA relative to ssMyBP-C in cardiac and skeletal muscles. The
experiments presented in this study can be replicated at both low (2.0 µm) and high
(2.3 µm) sarcomere lengths to determine whether the MyBP-C N-termini could
regulate LDA and whether to the same degree. This was not pursued due to purely
experimental reasons: the fragility of the papillary fibers and the time-consuming
nature of the experiment precluded additional experiments at high SL. Switching to
trabeculae or skeletal muscle fibers, which are more stable, may allow us to conduct
serial measurements of the same fiber at low and high SL. Furthermore, narrowing
the focus to just ssMyBP-C or fsMyBP-C would also free up time in a day in which to
do experiments.
Removing the effects of endogenous MyBP-C
Because the experiments used WT rats as the baseline model system, the
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presence of endogenous cMyBP-C in our studies complicates interpretation
of the results. The alternative is to use papillary muscles from one of two cMyBP-C
knock-out mouse models that originated from the Moss and Seidman group (Harris
et al., 2002; McConnell et al., 1999), and continue pursuing experiments involving
the FSKO, SSKO, and DSKO mice. Our objective was to determine the baseline
physiological function of MyBP-C N-termini, and thus we did not pursue using these
knock-out models as the baseline model several reasons. First, both the Moss and
Seidman mouse models exhibit cardiac disease phenotype, specifically HCM and
DCM, respectively. The contribution of fibrosis alone could mask several parameters
that we measured. Second, the mouse model presents particular challenges. Mouse
papillary muscles are smaller and would not have yielded as many usable fibers as
rat papillary muscles. Given the context of our study with four experimental groups,
there would have been very slim margin of error for the trimming of papillary
muscles. In addition, mouse ventricular myocytes are also not nearly as robust as rat
ventricular myocytes. As such, our culture experiments would have required
additional time and expertise, with comparatively little payoff. Rat and mouse
cardiomyocyte culture experiments were pursued side-by-side, and our mouse
cardiomyocyte experiments were much less fruitful. Finally, the SSKO and FSKO
mice are simply so new that we do not know whether the absence of either ssMyBPC nor fsMyBP-C cause changes in morphology or exhibit a disease phenotype that
may complicate function. All of these together indicated a simpler system using WT
animals for our initial experiments. That is not to say that these experiments are not
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worth pursuing. On the contrary, they would be very informative on two
fronts. They would validate whether the functional results we observed in WT
systems were accurate and not obfuscated by endogenous MyBP-C. Moreover, these
experiments would be interesting in whether N-termini are sufficient to rescue
function in disease states.

CHAPTER ELEVEN
FINAL THOUGHTS
Based on my data, ssMyBP-C and fsMyBP-C regulation of contraction is
limited to low and high ranges of Ca2+, respectively, while cMyBP-C regulation
extends over the full spectrum of Ca2+. This interpretation is supported by the role
of cardiac versus skeletal muscles: the cardiac sarcomere is exposed to a wide and
dynamic range of Ca2+ on a beat-to-beat basis. Conversely, skeletal muscles are not
contracting and relaxing every second and therefore not exposed to the same range
of Ca2+ with the same frequency. Various skeletal muscles also have different
purposes: postural muscles have different roles than locomotor muscles. Therefore,
skeletal muscles can fine-tune the role of specific muscles by expressing different
amounts of slow- and fast-skeletal MyBP-C to accommodate the role of specific
skeletal muscles. cMyBP-C has been demonstrated to be highly tunable via posttranslational modification (Colson et al., 2012; Colson et al., 2016; Jia, Shaffer,
Harris, & Leary, 2010), and such modifications can potentially act on actin and
myosin at different contractile stages as either facilitator, inhibitor, or both. Such
modifications to each MyBP-C isoform structure and function deserve further
studies, particularly in light of the vast amount of information that can be elucidated
from the study of multiple isoforms together. The convergence of steady-state and
dynamic experiments in the present study, as well in vitro and in silico methods all
suggest MyBP-C isoforms are distinctive in their regulation of muscle contraction.
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CHAPTER TWELVE
MATERIALS AND METHODS
Expression and Purification of Recombinant MyBP-C proteins
Recombinant proteins representing the N-terminal domains up to the C2 domain of
slow-skeletal, fast-skeletal, and cardiac (ssC1C2, fsC1C2, and C0C2, respectively)
were generated, purified, and analyzed with SDS-PAGE(Govindan et al., 2012)
(Figure 10). Each MyBP-C isoform was expressed using a pET28 Expression system
(Millipore 70777) in E. coli, and included an N-terminal His-tag consisting of six
histidine residues. Protein expression in BL21 was induced by IPTG and purified
through a nickel-nitrilotriacetic acid affinity column in which eluted fractions were
combined and dialyzed in PBS. Recombinant proteins were used in all following
steady-state biophysical studies to determine the functional differences between the
slow-skeletal, fast-skeletal, and cardiac isoforms of MyBP-C. Details regarding the
transcript and amino acid sequence of N-terminal peptides can be found in Table 1.
Recombinant proteins were quantified and the volume required for the final desired
concentration was calculated. Proteins were then aliquoted, lyophilized, and stored
at -80°C until ready for use in fiber experiments.
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Papillary Muscle Fiber Bundle Preparation
Male Sprague-Dawley rats (250g) (Harlan) were euthanized using
Beuthanasia in accordance to Institutional Animal Care and Use Committee protocol
at Loyola University Chicago. The whole heart of the rat was rapidly excised
underwent retrograde perfusion with Krebs-Henseleit Buffer (KHB) via proximal
aorta. The heart was cut to carefully expose the papillary muscles in the left
ventricle. Papillary muscles were carefully excised under a dissecting scope (Zeiss
Discover.V8 Stereo, PlanAPO S 0.63x FWD 81mm) and permeabilized overnight in
1% Triton X-100 (Sigma) in mounting relaxing solution (6.3 mM ATP, 6.48 mM Mg
Cl2, 10mM EGTA, 10 mM Na2CrP, 49.76 mM Kprop, 100 mM BES, pH 7) at 4°C,
removing cell membrane and membrane-bound proteins. After overnight
permeabilization, papillary muscles were further trimmed into fiber bundles
approximately 1 mm in length under the dissecting microscope (Figure 11).
Straight and parallel fiber bundles were selected based on uniformity and attached
at each end with aluminum t-clips. Images were taken under the dissecting scope
using an attached digital camera (Canon EOS Rebel T3i). Each fiber bundle was
gently cleansed by transferring between a series of 4 washes containing fresh
relaxing solution on ice and used within 12 hours. The t-clipped fibers were
attached to a force transducer (BAM21-LC; World Precision Instruments, Sarasota,
FL) and high speed length controller (Aurora Scientific, Inc.). Muscle dimensions
(cross-sectional area, length, and volume) were determined using an ocular
micrometer mounted in the dissection microscope (resolution, ~10 μm). These
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muscle dimensions were used to normalize contractile force, sarcomere length (SL)
and ATPase activity. SL was measured in passive relaxed condition by laser
diffraction as previously described(de Tombe & ter Keurs, 1990), adjusted to and
maintained at 2μm. Briefly, a helium-neon laser beam was directed through the
isolated muscle fiber bundle, in which muscle striation pattern diffract the laser
beam into a diffraction pattern. The striations of the muscle fiber bundle act as a
grating, with known angles of diffraction, and the projected pattern can therefore be
used to measure average SL.
Skeletal Muscle Fiber Preparation
Skeletal muscles were permeabilized as previously described (Wood et al.,
1975). Extensor digitorum longus (EDL) and soleus (SOL) muscles were excised from
the legs of FSKO mice. Care was taken to limit the damage to the muscle fibers by
cutting at the tendons, followed by submergence in 4°C relax solution (67.93 mM
KOH, 6.24mM ATP, 10mM EGTA, 10mM Na2CrP, 47.58 Kprop, 100 mM BES, 6.54 mM
MgCl2, pH 7). Fiber muscles were attached to short sticks by tying surgical sutures
around the muscle tendons, under a dissecting scope (Zeiss Discover.V8 Stereo,
PlanAPO S 0.63x FWD 81mm). These ‘muscles-on-a-stick’ were then submerged in
1:1 glycerol/relax solution in a 5 mL conical tube and stored at -20°C for at least two
weeks prior to use in functional assays. The purpose was two-fold: 1) to ensure
optimal permeabilization and 2) to cryoprotect the muscle fibers for long-term
storage. After at least two weeks, fibers were taken out and split into smaller fiber
bundles of approximately 1 mm in length and t-clipped. Images were taken under
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the dissecting scope using an attached digital camera (Canon EOS Rebel T3i). Each
fiber bundle was gently cleansed by transferring between a series of 4 washes
containing fresh relaxing solution on ice and used within 12 hours. The t-clipped
fibers were attached to a force transducer (BAM21-LC; World Precision
Instruments, Sarasota, FL) and high speed length controller (Aurora Scientific, Inc.).
Muscle dimensions (cross-sectional area, length, and volume) were determined
using an ocular micrometer mounted in the dissection microscope (resolution, ~10
μm). These muscle dimensions were used to normalize contractile force, sarcomere
length (SL) and ATPase activity. SL was measured in passive relaxed condition by
laser diffraction as previously described(de Tombe & ter Keurs, 1990), adjusted to
and maintained at 2.5μm. Briefly, a helium-neon laser beam was directed through
the isolated muscle fiber bundle, in which muscle striation pattern diffract the laser
beam into a diffraction pattern. The striations of the muscle fiber bundle act as a
grating, with known angles of diffraction, and the projected pattern can therefore be
used to measure average SL.
Incubating with MyBP-C N-termini
The permeabilized fibers were incubated with 10 μM of the ssC1C2, fsC1C2,
and C0C2 recombinant proteins or unincubated for 3 minutes in relaxing solution,
followed by 3 min in preactivating solution, before measuring force in activating
solution (Witayavanitkul et al., 2014). Activating solution contained 20 mM Ca2+EGTA, 1.55 mM potassium propionate, 6.59 mM MgCl2, 100 mM N,N-bis (2hydroxyethyl) taurine; N,N-Bis-(2-hydroxyethyl)-2-aminoethanesulfonic acid, 5 mM
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sodium azide, 1 mM DTT, 10 mM phosphoenolpyruvate, 0.01 mM oligomycin, 0.1
mM PMSF, and 0.02 mM A2P5, and a commercial protease inhibitor cocktail
(Sigma). Relaxing solution was the same as activating solution, but contained n20
mM EGTA, 21.2 mM potassium propionate, 7.11 mM MgCl2, and no calcium.
Preactivating solution was the same as the activating solution, but contained 0.5 mM
EGTA, 19.5 mM 1,6-diaminohexane-N,N,N,N’-tetraacetic acid, 21.8 mM potassium
propionate, and no calcium. All solutions contained 0.5 mg/ml pyruvate kinase and
0.05 mg/ml lactate dehydrogenase (Sigma) and had an ionic strength of 180 mM, 5
mM free ATP, and 1 mM free magnesium. Recombinant proteins were present in
relaxing and preactivation solutions for subsequent measurements. Activation
solution did not have recombinant proteins present to avoid potential complications
with changes in Ca2+ levels. Isometric tension and ATPase activity were measured at
various levels of Ca2+ activation as previously described(de Tombe & Stienen, 1995;
Rundell, Manaves, Martin, & de Tombe, 2005). Briefly, the isolated muscle was
exposed to a range of calcium solutions obtained by proportional mixing of
activating and relaxing solutions. The force generated and ATP consumed were
measured simultaneously during the contraction.
Force-pCa, Force-ATPase, and rate of tension redevelopment
Force-pCa relationship was determined by titrating the activation and
relaxing solutions(Witayavanitkul et al., 2014). Maximal isometric tension was
measured at 100% activation solution, followed by sequential washes in relaxing
and preactivating solutions for 5 minutes each. However, subsequent measurements
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of isometric tension occurred in solutions titrated with decreasing ratio of
activation-to-relaxation solutions: 95%, 90%, 85%, 80%, 70%, and 0% activation
solution, which corresponded to pCa values of approximately 4.50, 5.11, 5.42, 5.61,
5.77, 6.00, and 10.00, respectively, as determined by the Fabiato program (van der
Velden, Moorman, & Stienen, 1998). The integrity of the fibers was tested
afterwards by measuring maximal tension after the experiment. Any fibers that did
not maintain 80% or greater maximal tension were excluded from analysis. ForceATPase relationship was determined using an optical absorbance enzyme
assay(Guth & Wojciechowski, 1986). Briefly, ATP consumption was determined by
measuring the absorbance of UV light at wavelength 340 nm. ATP hydrolyses into
ADP and inorganic phosphate inside the fiber, which is stoichiometrically coupled to
the oxidation of NADH to NAD+. This oxidization reaction is catalyzed by pyruvate
kinase and lactate dehydrogenase in our activating solutions. NADH, but not NAD+,
absorbs light specifically at 340 nm. A series of 50 nl of 10 mM ADP were injected
into the measuring chamber. Each injection of ADP induced a rapid reduction in
fluorescence and allowed the calculation of the rate of ATP consumption,
determined by measuring the fluorescent decay rate at 340 nm. After completion of
the Force-ATPase assay, papillary muscles underwent a rapid release-restretch
maneuver in order to break previously formed cross-bridges and allow crossbridges to reform. The rate constant of tension redevelopment (ktr) was then
measured at maximal activation, as previously described(Rundell et al., 2005;
Swartz & Moss, 1992). Force-pCa and Force-ATPase relationships were fitted with a
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modified Hill equation(Chandra et al., 2001; Rundell et al., 2005; Sumandea et al.,
2003). Stiffness and tension costs were fitted linearly to the Force-stiffness and
Force-ATPase data, respectively. (Figure 14,15,33,34) Stiffness is a measure of
attached cross-bridges and is proportional to tension. Stiffness is measured by
applying rapid, oscillating length changes and recording the change in force
(Δforce/Δlength) (Ford et al., 1977).
Actin cosedimentation
Assay cosedimentation was conducted on recombinant MyBP-C proteins, as
previously described(Kuster et al., 2015; Shaffer et al., 2009). Increasing
concentrations of ssC1C2, fsC1C2, and C0C2 (1 – 30 µM) was added to 5µM F-actin
(Cytoskeleton AFK99A) in cosedimentation buffer that contained 1mM ATP and
DTT. Reactions were allowed to equilibrate for 30 minutes at room temperature.
Samples were spun in an ultracentrifuge (Beckman) for 30 minutes, 100,000 RPM,
using a TLA 100 rotor at 4oC. Supernatants were removed and pellets gently washed
with cosedimentation buffer, followed by an additional spin. Samples were then
dissolved in a 1:1 cosedimentation/urea buffer for 5 minutes at room temperature.
4x Laemmli buffer was added to the samples and run on a 10% SDS-PAGE gel. Along
with the sample preparations, standard curves were run along side, consisting of
increasing amounts of MyBP-C N-termini (4-40 pmol) and F-actin (40 pmol) for a
molar ratio of 0.10, 0.20, 0.35, 0.50, 0.65, 0.80, 1.00 (Figure 20). Gels were stained
with coomassie blue R-250 solution (0.05% in 25% isopropanol, 10% acetic acid)
and imaged using ChemiDoc imager (Bio-Rad). Densitometry analysis of sample
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bands was conducted with ImageJ (NIH) and the intensity ratio of MyBP-C to F-actin
was converted to a molar ratio using the standard curve. Cosedimentation sample
curves were fit to a one-site, specific binding nonlinear regression. Combined
ssC1C2, fsC1C2, and C0C2 cosedimentation curves were generated (Figure 21). Bmax
and Kd values were obtained from this fit and given in Table 4.
Computational modeling
We used an adapted version of computational model that had been
previously demonstrated to predict changes in unloaded shortening of individual
cardiomyocytes(Campbell et al., 2013). The Online Muscle Simulation (OMS) was
made available online: http://onlinemusclesim.org/ and the myofilament model
accounts for length-dependent activation and strain-dependent XB
kinetics(Razumova, Bukatina, & Campbell, 1999; Rice, Wang, Bers, & de Tombe,
2008), but not the contribution of MyBP-C. Since our goal is to model unloaded
shortening, in which individual cardiomyocytes are isolated, components
accounting for force(Rice et al., 2008; Sheikh et al., 2012) were set to zero.
Computer modelling accounts for results suggesting differential MyBP-C capacities
on thin filament activation, as defined as kon, or the rate of tropomyosin shift from
blocked to closed position (see Table 6). All other parameters were unchanged to
limit variability in our data and specifically determine whether thin filament
activation accounted for changes in relaxation kinetics.

147
Isolation of adult rat cardiomyocytes
Cardiomyocytes from adult Sprague-Dawley rats (250g) were isolated as
previously described (33). After isolation, cardiomyocytes were gradually switched
into plating media, which contained HMEM supplemented with 100U/mL
penicillin/streptomycin (pen/strep), 10% fetal bovine serum, and 10mM BDM. For
functional measurements, cardiomyocytes were plated on laminin-coated 25mm
coverslips. For protein analysis, cells were directly plated onto laminin-coated
35mm circular dishes. After 1-hour incubation, plating media was removed, and
culture media was added. Culture media consisted of HMEM, supplemented with
0.1% BSA, 100UmL pen/strep, 2mM glucose, 10mM BDM, and 5ug/mL
insulin/transferrin/selenium (ITS) supplement. Cells were kept in a 2% CO2
incubator to maintain a pH of 7.0 and maintained for 48 hours.
Adenovirus Infection and Cell Culture
Commercially purchased slow and fast skeletal MyBP-C clones from Origene
(NM_175418.3 and NM_004533, Rockville, MD) were used to construct the
adenoviruses used to overexpress skeletal isoforms of MyBP-C. Cardiac MyBP-C
adenoviral vectors were generated by the core facilities at Loyola University
Chicago. Adenoviral constructs were created by cotransfection of MyBP-C cDNA into
DH5α E. coli. Adenoviruses containing slow, fast, or cardiac MyBP-C included a CMV
promoter and c-Myc tag to distinguish between endogenous and adenovirusmediated MyBP-C protein expression. Uninfected cells and c-Myc-tagged cMyBP-C
overexpressing cells were used as experimental controls Adenoviral constructs
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overexpressing slow, fast, and cardiac MyBP-C (Multiplicity of Infection MOI: 1000)
were added to the culture media 1 hour after incubation and allowed to infect
cardiomyocytes for 24 hours. Culture media was changed after 24 hours, removing
the adenovirus and waste, and replenishing nutrients in the media.
Immunofluorescence Imaging
Cultured adult rat cardiomyocytes were plated in chamber slides (Lab-Tek II,
Thermo Scientific) for immunofluorescence imaging. After 48 hours in culture, cells
were rinsed twice with PBS and fixed with cold (4°C) 4% paraformaldehyde for 3
minutes, followed by 1 minute in ice cold (-20°C) methanol. Cells were then
permeabilized in 0.5% Triton X-100 in PBS (20 minutes), 0.1% Triton X-100 twice
(10 minutes), and antigen-retrieval solution (0.1M glycine, pH 7.4) (30 minutes),
and rinsed three times with PBS. Cells were blocked with 0.1% BSA, 0.1% gelatin,
0.1% tween-20, 0.0001%NaN3, and incubated with primary antibodies for ssMyBPC (ProSci 6679), fsMyBP-C (ProSci 5651), and rabbit c-Myc (1:500 Roche) and
mouse α-actinin (1:500 Sigma) overnight. After rinsing with PBS, corresponding
secondary antibodies (AlexaFluor rabbit 488 at 1:50 dilution and mouse 568 at 1:50
dilution) were added for 1 hour at room temperature, rinsed, coverslipped with
VectaShield mounting medium (Vector Labs H-1500 10mUL 1.5ug/mL) for imaging
with confocal microscopy. Images were taken using a Leica TCS SP5 and processed
using ImageJ (NIH).
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Western blot analyses
Detection of endogenous and de novo MyBP-C protein in cardiomyocytes was
determined by immunoblotting. Adenovirus infected cardiomyocytes were rinsed
with sterile PBS to remove culture media, followed by the addition of 60uL of urea
buffer. Cardiomyocytes were scraped off using a cell lifter (Fisher Scientific) and
pipetted into 0.6mL tubes. 25uL of 4x loading dye (0.4% bromophenol blue, 10% ßmercaptoethanol) was then added. Samples were heated at 100°C for 5 minutes,
separated by gel electrophoresis in 10% SDS-PAGE gels, and blotted onto
nitrocellulose membrane at 300 mA for 3 hours. Detection of protein was
determined by using antibodies for c-Myc, ssMyBP-C, fsMyBP-C, and cMyBP-C
(Sigma C3956, ProSci 6679, ProSci 5651, Santa Cruz sc-137180, respectively)(B. Lin
et al., 2013) (Figure 26). Quantification of replacement levels was determined by
densitometry analysis normalized to ß-actin loading controls, using ImageJ (NIH).
Replacement levels were calculated by signal of cMyc/(cMyc + cMyBP-C), as
previously described(Metzger, Michele, Rust, Borton, & Westfall, 2003).
Unloaded shortening in cultured adult rat ventricular cardiomyocytes
After 48 hours in culture, HMEM media was incrementally replaced with
Tyrode’s solution (135 mM NaCl, 4 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM dglucose, 10 mM HEPES) to limit damage to the cells. Coverslips with attached
cardiomyocytes were transferred to a custom stimulation chamber containing
platinum electrodes. The chamber was then fitted onto a Nikon microscope stage
and stimulated (2.0 ms pulse, 1 Hz, and 20V). Sarcomere length and SL shortening
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were measured by a video-based detection system (Ionoptix, Milton, MA). Analysis
of contractile function was determined from an average of 10 contractions of
individual cardiomyocytes, with 10-20 cardiomyocytes measured per coverslip
preparation.
Determination of fsMyBP-C expression in heart failure samples
Surgical procedures for TAC (transverse aortic constriction) and sham
FVB/N mice were performed(Verma et al., 2012), and TAC mice developing
pressure-overload hypertrophy. The transverse aorta was constricted by 7-0 silk
suture, with a blunt 27 GA needle to standardize the size of constriction. After 12
weeks, RNA from hearts of TAC and sham mice (n=3 per group) were isolated and
purified to make cDNA using the iScript cDNA synthesis kit (BioRad 1708891).
cDNA libraries were generated, sequenced, and aligned(Christodoulou, Gorham,
Herman, & Seidman, 2011). Number of reads aligned were normalized per million.
Significant changes in gene expression was determined as ≥ 1.5-fold increase for
upregulation and ≤ 0.6 fold decrease for downregulation, using the BenjaminiHochberg false discovery rate test at p < 0.001. Validation of RNA-Seq data was
determined by analysis of mRNA levels using qPCR. Samples for qPCR used TaqMan
primers against MYBPC2 with GAPDH as a reference gene (Applied Biosystems
Mm00525419m1 and Mm00486742m1, respectively). The qPCR analysis was
performed on a thermocycler (BioRad CFX96) with the following protocol: 10
minutes at 94oC, 40 cycles of 15 seconds at 94°C and 60 seconds at 60°C. Analysis of
normalized gene expression was then computed with an amplification efficiency
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corrected ΔΔCq equation(Pfaffl, 2001). (see Figure 5)
Statistical Analysis
Data were analyzed using Benjamini-Hochberg False Discovery-Rate
Test(Reiner, Yekutieli, & Benjamini, 2003). For this test, a fold change 0.6 fold down
or 1.5 fold up, and p < 0.001 was considered significant. TPA experiments were
analyzed using an unpaired t–test. All other data are presented as means ± SEM,
unless otherwise indicated. Statistical significance for all other experiments were set
at p<0.05.
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